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Abstract / Resumen 
Breast cancer is the leading cause of cancer death of women in developed 
countries. In particular, triple-negative breast cancer is highly aggressive with reduced 
therapeutic options since lacks well-defined molecular targets and is very 
heterogeneous. It is defined by the absence of Estrogen receptor (ER), Progesterone 
receptor (PR), as well as, Human epidermal growth factor receptor 2  (HER2) and 
constitutes 10 – 20% of all breast cancer. Besides, it has been described that Src 
family kinases (SFKs) are involved in the development of human cancers, including 
breast cancer. Increases in SFKs activity is correlated with the progression of 
malignancy. Overexpression of c-Src or aberrant activation has been identified in 
various human cancers. Src is an essential component of several signalling pathways 
that regulate proliferation, survival, angiogenesis and metastasis.  
This Doctoral Thesis is focused on unrevealing the mechanisms that depend on 
SFKs catalytic activity or on c-Src that lead to metastasis of the triple-negative/basal-
like breast cancer cell line, MDA-MB-231. To accomplish this objective we have used 
three complementary approaches: inhibition of SFKs catalytic activity by using three 
selective inhibitors, Dasatinib, PP2 and SU6656; conditional expression of shRNA-c-
Src or conditional expression of dominant-negative Src (SrcDN; K295M/Y527F).  
We found that SFKs catalytic activity controlled cell proliferation at G1-S phase 
transition by regulating p27Kip1 and c-Myc expressions, by using Dasatinib and PP2. In 
contrast, SU6656 provoked polyploid cells, a SFKs-independent effect caused by 
concomitant inhibition of Aurora B kinase. Furthermore, SFKs inhibition and c-Src 
depletion reduced cell migration and invasion capabilities of MDA-MB-231 cells by 
reducing phosphorylation of Src substrates, Y925-Fak, p130CAS, Y118-paxillin and 
Y14-caveolin 1, required for focal adhesion turnover and cell motility. The expression of 
SrcDN showed an additional pathway, through Akt activation, involved in cell migration 
and invasion. Besides, c-Src modulated the secretion of proteins involved in breast 
cancer progression and metastasis, including Cyr61, IGFBP4 and CTGF. We found a 
new exosomal protein, Cyr61, which regulated invasion and transendothelial migration, 
important for extravasation of tumour cells. Furthermore, c-Src modulated the survival 
of MDA-MB-231 cells in anchorage-independent conditions, as well as, was required to 
maintain the breast cancer stem/progenitor cell subpopulation by regulating the 
expression of pluripotency-associated transcription factors Oct3/4, Nanog and Sox2.  
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Abstract / Resumen 
El cáncer de mama es la principal causa de muerte por cáncer en mujeres de 
países desarrollados. Concretamente, el cáncer de mama triple negativo es muy 
agresivo con reducidas opciones terapéuticas, ya que, carece de dianas moleculares 
claramente definidas y es muy heterogéneo. Se caracteriza por la ausencia de 
receptor de estrógeno (ER), receptor de progesterona (PR), así como, del receptor del 
factor de crecimiento epidérmico humano 2 (HER2) y constituye entre un 10-20% de 
todos los cánceres de mama. Además, se ha descrito que la familia de proteínas 
tirosina quinasa de Src (SFKs) está implicada en el desarrollo de cánceres humanos, 
incluido el cáncer de mama. La sobreexpresión de c-Src o la activación anormal se 
han identificado en varios cánceres humanos. Src es un componente esencial de 
varias vías de señalización que regulan proliferación, supervivencia, angiogénesis y 
metástasis. 
Esta Tesis Doctoral se centra en desentrañar los mecanismos que dependen de la 
actividad catalítica de SFKs o de c-Src y que conducen a la metástasis de la línea 
celular de cáncer de mama triple negativa de tipo basal, MDA-MB-231. Para lograr 
este objetivo hemos usado tres aproximaciones complementarias: inhibición de la 
actividad catalítica de SFKs utilizando tres inhibidores selectivos, Dasatinib, PP2 y 
SU6656, expresión condicional de shRNA-c-Src o expresión condicional de Src 
dominante negativo (SrcDN; K295M/Y527F). 
Nosotros encontramos que la actividad catalítica de las SFKs controla la 
proliferación celular en la transición G1-S mediante la regulación de la expresión de 
p27Kip1 y c-Myc, usando Dasatinib y PP2. En cambio, SU6656 provocó poliploidía 
celular, un efecto independiente de las SFKs causado por la inhibición simultánea de 
Aurora quinasa B. Además, la inhibición de las SFKs así como el silenciamiento de c-
Src redujeron la capacidad migratoria e invasiva de las células MDA-MB-231 mediante 
la disminución de la fosforilación de los sustratos de Src, Y925-Fak, p130CAS, Y118-
paxilina and Y14-caveolina 1, necesaria para el recambio de las adhesiones focales y 
la motilidad celular. La expresión de SrcDN mostró una vía adicional, mediada por la 
activación de Akt, implicada en la migración e invasividad celular. Además, c-Src 
moduló la secreción de proteínas implicadas en la progresión y metástasis del cáncer 
de mama, incluyendo Cyr61, IGFBP4 y CTGF. Encontramos una nueva proteína 
exosomal, Cyr61, que reguló la invasión y la migración transendotelial, importante para 
la extravasación de las células tumorales. Además, c-Src moduló la supervivencia de 
las células MDA-MB-231 en condiciones de independencia de anclaje y era necesaria 
para el mantenimiento de la subpoblación de células troncales/progenitoras de cáncer 
de mama, a través de la regulación de la expresión de los factores de transcripción 
asociados a pluripotencia Oct3/4, Nanog y Sox2. 
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Introduction 
1. BREAST CANCER 
 
 Breast cancer is a heterogeneous group of diseases characterized by loss of 
growth control, and disrupted tissue organization and differentiation (22). 
 
1.1. Mammary gland structure and development 
Mammary glands are secretory organs composed of distinct cell types: epithelial 
cells, adipocytes, infiltrated vascular endothelial cells, fibroblasts and immune cells. 
The inactive adult mammary gland is composed of 15 to 20 irregular lobes separated 
by connective tissue. The lobes radiate from the nipple and are further subdivided into 
several lobules termed terminal duct lobular units (TDLUs), the basic units of the  
mammary gland (85). The ductal epithelium is a bilayered structure that comprises two 
main cell types: basal and luminal. The outer layer of the gland consists of contractile 
myoepithelial basal cells and a small population of stem cells, which supply the 
different cell types. The inner layer is composed of secretory luminal epithelial cells 
(120) (Figure 1). 
The mammary gland development occurs through three main stages: 
embryogenesis, puberty and adulthood; undergoing major changes during pregnancy 
and reaching its full developmental potential during the lactation phase. At the end of 
embryogenesis a rudimentary ductal system is generated by cues from mesenchyme. 
The mammary gland remains relatively quiescent until puberty. During puberty ductal 
morphogenesis occurs under the influence of hormones, including Growth hormone 
(GH), estrogen and Insulin-like growth factor-1 (IGF1), as well as, growth factors such 
as Epidermal growth factors (EGFs) and Fibroblast growth factors (FGFs). In the 
adulthood the gland undergoes mild proliferation and differentiation regulated by 
progesterone, as well as minor involution during the murine oestrus cycles; similar 
changes occurs in humans during the menstrual cycles. During pregnancy, 
progesterone together with prolactin provoke an extensive side-branching, making 
more complex TDLU structure, that finally forms secretory acinar structure. Prolactin 
stimulation continues to generate lactational competence of the mammary gland. The 
absence of suckling signals provokes the mammary gland involution, characterized by 
the apoptosis of acini cells and remodelling of lobular-alveolar structures. Matrix 
metalloproteases (MMPs) participate in this remodelling by degrading components of 
basement membrane and extracellular matrix (ECM) (76,120). 
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1.2. Incidence and biology of breast cancer 
Breast cancer is the most frequent type of malignancy and the leading cause of 
cancer deaths of women in developed countries; it constitutes 23% of total cancer 
cases and 14% of the cancer deaths. Incidence rates are high in Western, Northern 
Europe, Australia/New Zealand, and North America and low in sub-Saharan Africa and 
Asia (52). 
Breast cancer progresses from benign epithelial atypia and atypical ductal 
hyperplasia (ADH), to malignant ductal carcinoma in situ (DCIS), or less frequently 
lobular carcinoma in situ (LCIS), and finally to invasive ductal carcinoma (IDC). DCIS 
consists of disorganized malignant cells that express E-cadherin and are enclosed by 
the basement membrane. However, in invasive ductal carcinoma cells break through 
the basement membrane and spread to the surrounding breast tissues. (22). 
The breast cancer staging is based on the TNM (Tumour, Node, Metastasis) 
classification of primary tumour. The stage of a patient is designated after knowing the 
localization, size and spreading of primary tumour, as well as, the regional lymph 
nodes affectation and the appearance of metastases. The main stages are 0, I, II, III 
and IV, being stage 0 in situ, stage I early invasive state, and it progress to the stage IV 
which presents distant metastases. Normally the stage is inversely related to prognosis 
(45). 
 
 
 
Figure 1. Mammary gland structure. (A) Sagital section of the mammary gland. Adapted from © 2012 
Terese Winslow LLC. (B) Cellular structure of the mature mammary duct, composed of a myoepithelial 
layer and a luminal layer with stem cells. Adapted from Tiede et al. 2011. 
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1.3. Types of breast cancer 
Invasive ductal carcinomas can be classified into subtypes that have distinct 
histological features, molecular expression signatures and clinical outcomes. The five 
major subtypes based on the immunohistochemical expression of Estrogen receptor 
(ER), Progesterone receptor (PR) and Human epidermal growth factor receptor 2 
(HER2 or ERBB2) are: basal-like, HER2-like, normal breast–like, luminal A, and 
luminal B. Basal-like tumours are characterized by expression of cytokeratin-5 and 
cytokeratin-17; HER2-like overexpress HER2 and related genes; normal-breast like 
tumours, express genes from adipose and other non-epithelial cells. Luminal A and B 
are ER positive tumours with high levels of cytokeratin-8 and cytokeratin-18; they differ 
in the levels of ER expression, as well as, in the proliferation rate (36,96,109).  
A breast cancer group highly aggressive with reduced therapeutic options due to 
their heterogeneity and the absence of well-defined molecular targets is triple-negative 
breast cancer (TNBC). TNBC is characterized by the absence of ER expression, as 
well as, PR and does not have HER2 amplification. The majority of TNBC are basal-
like (50-70%) (2); although, a new subtype was recently defined, termed claudin-low. 
This subtype was originally included in basal-like subtype, although it exhibits its own 
molecular characteristics including down-regulation of claudin-3, claudinin-4 and 
claudinin-7, reduced expression of Ki67, increased expression of epithelial-
mesenchymal transition markers and of mammary cancer stem cells (CSCs) markers 
such as CD44+,CD24-/low phenotype (48). TNBCs constitute 10 – 20% of all breast 
cancer and more frequently affect younger patients (67).  
Among TNBCs basal-like (recently assigned as claudin-low subtype), a commonly 
studied cell line is the MDA-MB-231 (48). This human epithelial cell line was 
established from pleural effusion and is characterized by epidermal growth factor 
receptor (EGFR) overexpression and carries a mutant tumour suppressor protein p53 
(23).  
 
2. SRC FAMILY KINASES 
 
In 1911, Peyton Rous discovered a virus that caused tumours in chickens, later 
termed Rous sarcoma virus (RSV). Years later, v-src was defined as the only RSV 
gene required for cell transformation. At the late 70’s, the v-src gene product, pp60 v-src, 
or v-Src, was identified as the first protein tyrosine kinase. During this time, the 
counterpart cellular homologue c-Src was discovered, which allowed to establish the 
concept of proto-oncogene (10,78,79). 
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 c-Src is the prototypic member of the Src family of tyrosine kinases (SFKs) that 
comprises nine members, c-Src, Yes, Fyn, Lyn, Blk, Lck, Hck, Fgr and Yrk. Three of 
them, c-Src, Yes and Fyn are ubiquitously expressed whilst Lyn, Blk, Lck, Hck, Fgr and 
Yrk are mainly expressed in hematopoietic cells (37,119). 
 
2.1. Structure and regulation of SFKs 
All family members have a conserved domain organization: a myristoylated and/or 
palmitoylated amino-terminal region, important for membrane localization; a unique 
domain, which varies the most among Src family members; SH3 and SH2 scaffold 
domains and a linker between SH2 and kinase domains. The catalytic domain is 
composed of two lobes separated by the catalytic cleft, where the ATP-binding site 
(K298) and substrate-binding site are located; the cleft contains the activation loop, 
which controls the accessibility of substrates and has a positive-regulatory 
autophosphorylation residue Y419 within the activation loop. The carboxyl-terminal tail 
has the negative-regulatory Y530 (Figure 2).  
The inactive close conformation of SFKs occurs when Y530 at C-terminal domain is 
phosphorylated and binds to SH2 domain. Besides, this interaction is stabilised by 
binding of SH3 domain to the linker region. The result is a close molecular structure 
with a reduced access of substrates to the kinase domain. When SFKs is activated the 
intramolecular interactions are lost, giving rise to an open conformation. The active 
conformation of Src is stabilized by autophosphorylation at Y418 (Figure 2). 
Chicken c-Src and human c-Src share a common structure, although differs in three 
amino acids that are present in the unique domain of human c-Src. On the other hand, 
v-Src contains 12 substituted carboxy-terminal amino acids, several point mutations 
throughout the molecule and does not have C-terminal regulatory region, thus is 
constitutively active. 
c-Src can be regulated by several mechanisms, including intramolecular regulation, 
activation mediated by receptor or by localization. Concerning intramolecular regulation, 
c-Src tyrosine kinase (CSK) and its homolog Csk-homologous kinase (Chk) are able to 
inactivate c-Src by phosphorylation of Y530. Conversely, this phosphorylation can be 
removed by several tyrosine phosphatases such as Protein tyrosine phosphatase-α 
(PTPα), Protein-tyrosine phosphatase 1B (PTP1B), SH2-containing tyrosine 
phosphatase 1 (SHP1) or SHP2. Activation of growth-factor and cytokines receptors, 
including EGFR, PDGFR, IGF1R, VEGFR, FGFR, HER2 and ER, leads to their 
association with SH2 domain, which displaces inhibitory intramolecular interactions to 
promote SFKs activation. The localization of SFKs is important for their regulation, 
since inactive SFKs are localized at perinuclear sites, and active SFKs indirectly 
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interact by their SH3 domain with actin to be translocated to the plasma membrane. 
The localization of SFKs allows for interactions with transmembrane receptor tyrosine 
kinases and integrins. Other mechanisms of SFKs regulation include ubiquitylation to 
be degraded by proteasome (133). Src is normally found in an inactive state in 
quiescent cells and it is transiently activated during the G1 phase for induction of DNA 
synthesis and at the G2/M transition for cell division. SKFs are constitutively activated 
in aberrant conditions, including cancer (10,119). 
 
 
 
 
 
 
 
2.2. SFKs in different types of cancer 
Among SFKs it is mainly Src that has been implicated in the development of human 
cancer. Like oncogenic v-Src, activated mutants of c-Src can transform cells in culture 
and induce tumours in chickens (37). Increases in Src kinase activity correlates with 
the progression of malignancy (106). Overexpression of c-Src or aberrant activation 
have been identified in various human cancers, although activating mutations and 
genomic amplifications are very rare (49). In gastrointestinal-tract cancer such as 
colorectal cancer shows a progressive increase in c-Src activity as the tumour stage 
Figure 2. Structure and activation of c-Src. (A) Molecular structure of human c-Src. (B) Inactive 
conformation of human c-Src where phospho-Y530 from C-terminal region interacts with SH2 domain and 
linker region binds to SH3 domain. Dephosphorylation at Y530 results in an open active conformation. 
Adapted from Yeatman et al. 2004. 
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advances. Furthermore, an enhanced c-Src activity is observed in hepatocellular, 
pancreatic, gastric and oesophageal malignancies, as well as in breast, ovarian and 
lung cancers. In head and neck squamous cell carcinoma (HNSCC) and non-small cell 
lung carcinoma (NSCLC) cells, c-Src promotes cancer cell survival through STAT3 
signalling (106). Hepatocellular cancers and colon carcinomas overexpress c-Src whilst 
underexpress the negative regulatory c-Src molecule, CSK, leading to higher levels of 
c-Src activation (133). Increased activity and expression of Yes were observed in 
human melanoma cells respect to normal melanocytes, as well as, in brain melanoma 
metastatic cells lines. In pancreatic cancer c-Src participates in the cell growth, 
invasion and metastasis. In ovarian cancer c-Src has an important role, since down-
regulation of c-Src expression decreased anchorage-independent growth, tumour 
growth in mice, as well as, reduced VEGF expression and tumour vascularization. In 
bladder carcinoma, inhibition of SFK blocked epithelial-mesenchymal transition, 
suggesting that contributes to invasion. There are less evidences that link SFKs with 
brain and neuronal tumours, however, it has been shown that Src-Fak (Focal adhesion 
kinase) complex may enhance the proliferation of anaplastic astrocytoma cells by 
means of Extracellular signal-regulated kinase 2 (ERK2) activation as well as, the 
expression of cyclin D and E (111). 
 
2.3. SFKs in breast cancer 
A mouse model of mammary tumourigenesis consisting of mice carrying 
polyomavirus middle T antigen (PyVmT)  under the control of mammary-specific 
promoter (MMTV) developed mammary tumours. However, mice with disrupted c-Src 
function often developed cystic hyperplasia and less frequently tumours; indicating that 
c-Src is important for mammary tumourigenesis in this model (44). The MMTV/PyVmT 
model of breast cancer with mammary epithelial-specific c-Src disruption, shown that c-
Src deletion in mammary epithelium delays tumour onset and decreases tumour 
burden (77). Besides, it has been shown that high Src kinase activity is observed in 
breast cancer tissue compared with normal breast tissue (36,51). A sample-matched 
study revealed that 37 of the 52 pairs exhibit an increased Src family kinase expression 
or activity in the breast carcinoma tissue compared to matched normal tissue (99). 
Regarding breast tumour hormone receptor status, a study revealed a significant 
inverse correlation between ERα and Src expression levels. It is shown that Src protein 
levels are higher in ERα- and PR- compared to ERα+ and PR+ tumours; in fact, the 
highest levels are found in triple-receptor negative tumours (27). Subsequently 
confirmed by Tryfonopoulos and colleagues, that observed an increase of Src in triple-
negative compared to non triple-negative breast cancer samples, particularly of 
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membrane-associated Src (122).  Furthermore, Src activity is increased in invasive 
respect to noninvasive breast cancer cell lines. Inhibition of SFKs activity in breast 
cancer cell lines reduces motility and invasion (114). It has been reported that SFKs 
activation phosphorylates Phosphatase and tensin homolog (PTEN), promoting its 
inhibition, which triggers PI3K/Akt signalling pathway. Furthermore, in HER2-
overexpressing cancer cells, trastuzumab treatment exerts its antitumour activity by 
inhibiting Src binding to HER2. Thus, Src is not activated and provokes an increase in 
membrane location and activity of the tumour suppressor, PTEN (73,88).  
Likewise, we previously shown that the conditional expression of a dominant 
negative form of Src (SrcDN, K295M/Y527F) in the non-metastatic, oestrogen-receptor 
positive, MCF7 cell line, provokes a significant decrease of cell migration, proliferation 
and spreading, as well as, causes tumour regression in nude mice (41). 
These reports clearly show that Src family kinases play an essential role in cellular 
growth and proliferation, angiogenesis, migration and invasion. 
 
3. METASTATIC PROCESS 
 
Metastasis arises following the spread of cancer cells from a primary site and the 
formation of new tumours in distant organs. It represents the primary cause of cancer 
mortality (18). 
Metastasis is a multistep process that requires numerous and well-defined timed 
changes in the tumour. Tumour cells detach from surrounding tissue and move through 
the extracellular matrix (invasion), entering into the blood or lymph circulatory systems 
(intravasation). Tumour cells must survive into circulatory system reaching secondary 
sites where they extravasate and colonize the new target tissue. The small population 
of tumour cells may remain latent until it is reactivated and growths, giving rise to a 
secondary tumour. New blood vessels formation (angiogenesis) is required for further 
tumour expansion (Figure 3).  
Metastasis from solid tumours displays different organ tropism. In some cases it 
mainly involves one organ, such as prostate cancer metastasis to bone or sarcoma 
metastasis to lung; whilst in other cases it relapses in multiple organs, such as, triple-
negative breast cancers, skin melanomas and lung cancers (125). 
SFKs are involved in cancer metastasis by stimulating tumour cell migration and 
invasion that allow the entry into bloodstream. Furthermore, SFKs regulate cancer cell 
survival and proliferation, processes required for metastatic cell growth (43,119).  
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3.1. Role of SFKs in survival and proliferation 
The proto-oncogene c-Src is involved in the regulation of cell cycle progression. It 
participates in growth factor receptor signalling to promote DNA synthesis. Src exerts 
its effects through several mechanisms including Shc phosphorylation that triggers 
MAPK signalling, PI3K stimulation, as well as, activation and/or phosphorylation of 
receptor tyrosine kinases. Src activity is required during G1 phase to induce DNA 
synthesis, but also, is involved in G2/M transition. Cdk2 activates Src by 
phosphorylation during mitosis. Besides, microinjection of Src family neutralizing 
antibodies provokes cell arrested during mitosis (119). 
Src phosphorylates p27Kip1, which impairs inhibitory activity of p27Kip1 over cyclin E-
Cdk2, facilitating p27Kip1 proteolysis. Besides, elevated c-Src activity has reduced 
p27Kip1 levels (28). 
We have previously shown that SFKs regulate G1-S transition in the breast cancer 
cell line MCF7. The proliferation rate is reduced after SrcDN expression in serum-
starved, as well as serum- and EGF-supplemented conditions. It provokes an 
accumulation of cells in G1 phase and a reduction of activated Akt together with an 
Figure 3. Metastasis steps. Metastatic process starts with dissemination of cancer cells from the primary 
tumour and ends in the formation of clinically detectable macrometastasis. The thickness of the arrows 
represents the efficiency in each step. Residual tumour cells remaining after treatment (Rx). Taken from 
Vanharanta et al. 2013. 
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increase in p27Kip1 expression after serum or EGF stimulation (41). Liu et al. in MCF7 
obtained similar results by after c-Src knockdown or Src activity inhibition by PP2. They 
observed that Src regulates G1 progression by modulating p27Kip1, cyclin D1 and E 
expressions through Akt/GSK3β and ERK1/2 pathways.   
Integrin-dependent adhesion or growth factor-induced signalling stimulates Src, 
which in turn activates Fak, by phosphorylation at Y925. This event creates a binding 
site for the SH2 domain of Grb2, which transmits signal to MAPK (also termed ERK) 
pathway through Ras. However, signalling from integrins can occur by phosphorylation 
of Shc adaptor protein by Src, activating Ras/MEK/ERK pathway and cell cycle 
progression. Besides, phosphorylated Y397-Fak can bind p85 regulatory subunit of 
PI3K leading to stimulation of PI3K/Akt pathway, which enhances survival and 
proliferation (43). 
Src acts as a mediator in growth-promoting pathways, induced by a variety of 
growth factors and cytokines that promote breast cancer, including oestrogen, 
progesterone, prolactin and epidermal growth factor. 
Besides, Src is involved in activation of Signal transducer and activator of 
transcription (STAT) by receptors tyrosine kinase and, in breast cancer cell lines with 
high levels of EGFR, inhibition of Src reduced STAT3 activity (36). 
We have previously shown that c-Src participates in cell proliferation induced by 
prolactin through two independent signalling pathways, Fak-ERK1/2 and PI3K, which in 
turn promotes c-Myc and cyclin D1 expression in the human breast cancer cells T47D 
and MCF7 (1). 
 
3.2. SFKs in cytoskeletal rearrangement, cell adhesion and migration 
Src kinases are involved in cell adhesion and migration, which require 
spatiotemporal rearrangement of cytoskeleton. Two main subcellular structures 
regulate adhesion, invasion and motility, focal adhesions and adherens junctions, both 
of them are regulated by c-Src. Focal adhesions are dynamic structures where 
cytoskeletal and signalling proteins are recruited by integrins clustering that attach the 
extracellular matrix to the actin stress fibers. They may comprise up to 100 structural 
and signalling molecules such as talin, vinculin, α-actinin, tensin, etc. Among the 
multiple molecules of focal adhesions c-Src, Fak, p130CAS, ERK and paxillin, play 
essential roles in their regulation. Adherens junctions allow cells to adhere to each 
other, by homotypic interactions between E-cadherin molecules (Figure 4). Focal 
adhesions tend to inhibit cellular migration unless there is a disruption of adherens 
junctions. c-Src is able to disrupt cellular junctions when is activated and promotes the 
focal adhesions turnover (133).  
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Cell migration is a cyclic process that includes formation of cellular protrusions, 
lamellipodia and filopodia, at the cell front; formation of focal adhesions at the front and 
disassembly at the rear edge, contraction of cytoskeleton leading to cell propulsion of 
the cell body forward and finally cell-substrate detachment and retraction at the rear of 
the cell.  
The Rho family GTPases Rac1, Cdc42 and RhoA are important mediators of cell 
motility since regulate focal adhesions turnover and cytoskeleton dynamics. At the cell 
front, Src controls the formation of lamellipodia and filopodia by activating Rac and 
promoting Rho suppression through the phosphorylation of p190RhoGAP. At the cell 
rear, Rho activity is high where regulates the actin fiber assembly, as well as, the 
contractility. The integrin-mediated activation of Src allows localization of the Rho 
suppression pathway at leading edge. On the other hand, Rac and Cdc42 regulate the 
initial recruitment of cytoskeletal and signalling proteins into small focal complexes, 
whereas Rho controls the maturation of these complexes into bigger focal adhesions, 
as well as, focal adhesion lifetime. 
It has been shown that the Fak-Src complex, p130CAS, paxillin, ERK, and Myosin 
light-chain kinase (MLCK) are essential for adhesion turnover at the cell front. The Fak-
c-Src complex phosphorylates paxillin and p130CAS, which in turn recruit other 
Figure 4. Adherens junctions and focal adhesion. Adhesion in epithelial cells is mediated by two main 
structures, adherens junctions and focal adhesions. Adherens junctions facilitate cell-cell adhesion through 
E-cadherin homotypic binding. E-cadherins, in turn, bind to actin filaments by a molecular complex 
consisting of p120-catenin, α-catenin and β-catenin. c-Src associates with this complex. Focal adhesion 
complex is composed of α-integrin and β-integrin heterodimers that link extracellular matrix to actin 
cytoskeleton. The intracellular complex that connect integrins to actin filaments is composed of several 
proteins, including paxillin, talin, vinculin, tensin, α-actinin, Fak and c-Src. Taken from Yeatman et al. 2004. 
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molecules to focal adhesions, regulating actin cytoskeletal organization. Paxillin is 
phosphorylated in tyrosine in the dynamic adhesions, which provokes its disassembly. 
On the other hand, Fak-Src signalling controls contractility through ERK, which 
phosphorylates MLCK to regulate adhesion disassembly. Fak autophosphorylation at 
Y397 regulates efficient disassembly of focal adhesions (127). 
In addition, caveolin 1, a substrate of Src, could play an important role in cell 
motility. It has been described that caveolin 1 overexpression is associated with a 
basal-like phenotype and predicting a worse breast cancer patient prognosis. Grande-
García et al. shown that the phosphorylation of Y14-caveolin 1 by Src is necessary for 
polarization and directs motility of mouse fibroblasts. Caveolin 1–deficient cells have 
decreased Rho and increased Rac and Cdc42 GTPase activities (42). 
Furthermore, Joshi and colleagues shown that Rho signalling via Rho kinase 
(ROCK) promotes tumour cell migration and invasion by regulating focal adhesion 
turnover through phosphorylation of Y14-caveolin 1. Phosphorylated Y14-caveolin 1 by 
c-Src is linked to Rho/ROCK signalling. Besides, it is localized to membrane 
protrusions of tumour cells and associated to Rho activation, Fak stabilization in focal 
adhesions, increasing focal adhesion dynamics, as well as, cell migration. Activated 
Rho is localized to the leading edge of motile cells, including metastatic breast 
carcinoma. Furthermore, phosphoY14-caveolin 1 is expressed in several metastatic 
cells lines such as MDA-MB-231 or PC3 (57). 
For its part, p130CAS is phosphorylated in tyrosine by Src-Fak complex creating a 
binding site for the adaptor protein Crk. Crk interacts with DOCK180, which in turn, 
activates Rac, promoting actin polymerization, and in consequence cell migration (43). 
Furthermore, p130CAS overexpression may provoke an increase in tyrosine 
phosphorylation of Fak and paxillin. p130CAS can bind Src, independently from Fak, 
enhancing Src in an active state (83).  
 
3.3. SFKs role in invasion and transendothelial migration 
Invasion of surrounding tissues is the first step in metastatic cascade. Malignant 
tumour cells are able to degrade epithelial basal membrane, as well as, the 
extracellular matrix, reaching circulatory system. The Src-Fak complex plays an 
important role in invasiveness. Fak localizes to lamellipodia and to actin-rich plasma-
membrane protrusions enriched in metalloproteases, termed invadopodia. Src family 
kinase members control invadopodia formation, since they participate in cytoskeleton 
remodelling but also increase expression of metalloproteinases MMP-2 and MMP-9. 
Their expression is regulated by Src-Fak complex through c-JUN amino terminal 
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kinase (JNK) signalling pathway. The degradation of extracellular matrix components 
by MMPs is required for tumour invasion of surrounding tissues. Furthermore, the loss 
of E-cadherin, that forms adherens junctions, facilitates invasion. c-Src negatively 
regulates E-cadherin levels, which probably favours invasion (133). 
Besides, caveolin 1 is involved in MDA-MB-231 metastatic ability, since its silencing 
by shRNA reduces cell invasiveness. In particular, ROCK- and Src-dependent 
phosphorylation of Y14-caveolin 1 is important for cell migration and invasion (57). 
Abl interactor 1 (Abi1) is found in invadopodia and regulates their formation. 
Besides, Src signalling controls Inhibitor of differentiation protein 1 (Id1) expression, 
which in turn, modulates MMP-9 expression in MDA-MB-231 cell line (112).  
Src family kinase participates in transendothelial migration. In AGS gastric 
adenocarcinoma cells, Cyr61 increases Chemokine receptor 1 and 2 (CXCR1 and 
CXCR2) expression and transendothelial cell migration through integrin 
αvβ3/Src/PI3K/Akt pathway (68). VEGF, through Src kinase activity, disrupts 
endothelial barrier function, promoting tumour cell extravasation, as well as, lung and 
liver metastasis of murine CT26 colon carcinoma in mice (128).  
 
3.4. Role of SFKs in anchorage-independent growth 
An essential property of metastatic cancer cells is to survive in circulatory system in 
order to colonize distant sites. Metastatic cells avoid anoikis, programmed cell death 
induced by detachment from the extracellular matrix. In mammary epithelial cells, 
overexpression of EGFR and c-Src promotes anchorage-independent growth (30). 
Integrins initiate signalling by clustering and binding to extracellular matrix components. 
In pancreatic carcinoma cells recruitment of c-Src by integrin αvβ3 may promote 
anchorage-independent signalling, distinct from the Fak-dependent response provoked 
by integrin in adherent conditions. Furthermore, colony formation depends on 
p130CAS phosphorylation by c-Src. Besides, αvβ3  promotes anchorage-independent 
growth by means of c-Src in breast and cervical cancer cell lines (29). 
In addition, HEK293 cells transiently transfected with caveolin 1 (wt), c-Src and 
Grb-7,  shown an increase in the number of colonies as compare to cells transfected 
with the mutant caveolin 1 (Y14A) together with c-Src and Grb-7. Thus, 
phosphorylation of Y14-caveolin 1 by c-Src binds Grb7 which enhances anchorage-
independent growth (129). 
 
3.5. SFKs in breast cancer metastasis to bone, lungs, brain and liver 
The most common metastatic sites of breast cancer are brain, liver, lung, bone and 
distant nodal. Breast cancer cells express the chemokine receptors CXCR4 and CCR7 
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at high levels. CXCL12 and CCL21, the ligands for these receptors, are abundantly 
expressed in lymph nodes, lung, liver and bone narrow (18). Distinct patterns of 
spreading are shown based on the breast cancer subtype. Kennecke et al. made a 
study with 3726 patients showing that luminal A and B types have low risks of brain 
metastasis. HER2-like and luminal/HER2 (normal breast-like) subtypes have a 
relatively high rate of metastasis to brain, bone, liver and lung. Whereas basal-like 
tumours exhibit high rates of brain, bone, lung and nodal metastases and a lower rate 
of liver metastases. Moreover, the rate of early relapse is higher in basal-like and triple 
negative non-basal subtypes (58).  
Bone metastases from breast cancer cells are mainly osteolytic, caused by 
osteoclast stimulation (86). c-Src has a role in bone formation, since Src knockout mice 
are deficient in bone remodelling and develop osteopetrosis (108). In fact, it has been 
shown that c-Src kinase activity promotes the development of osteolytic bone 
metastases of MDA-MB-231 cells. Mice intracardiacally injected with MDA-MB-231 
transfected with constitutively active Src, developed larger osteolytic bone metastases 
compared to those observed with MDA-MB-231 expressing Src wt or Src kinase dead 
(87). In a study by Zhang and colleagues, MDA-MB-231 bone metastatic derivate cell 
line (BoM-1833) injected into left ventricle of mice caused dead with bone metastasis in 
70 days, meanwhile c-Src knockdown extended survival by approximately 25 days. 
Thus, Src plays an important role in bone metastasis by promoting survival of breast 
cancer cells in bone marrow, since Src is necessary for CXCL12 activation of Akt and 
cell survival, as well as, for resistance to the proapoptotic effect of TRAIL (138). 
Animal model of lung metastasis, consisting of tail vein injection, shown that after 
inoculation of Src kinase dead-transfected MDA-MB-231 cells, a lower number of foci 
was detected in lung with respect to inoculation of control cells. Therefore, Src tyrosine 
kinase activity has a role in lung metastases of MDA-MB-231 cells (87).  
Many patients with breast cancer finally develop brain metastasis with a survival of 
less than one year. Clinically, HER+ and TNBC patients have a higher risk for brain 
metastasis relapse. Zhang and colleagues observed an increased Src expression and 
activity in brain-seeking cell lines from BT474 and MDA-MB-231 compared to parental 
cell lines. Besides, immunohistochemistry of brain metastasis tumours revealed a 
strong staining of pY416-Src, that was significantly increased compared to primary 
breast tumours (unmatched). In an in vitro model of blood–brain barrier, they also 
observed that Src-wt or SrcY527F (constitutively active Src) promoted invasion, 
whereas shRNA-c-Src suppressed it. In addition, Src wt and Src-Y527F MDA-MB-231 
cells shown an increased brain metastasis in vivo respect to control cells (137). 
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Multivariate analyses of 615 human breast tumours demonstrated an association 
between SRS (Src-responsive signature) status, a gene expression signature that 
denotes Src activity, and liver metastasis for ER+ patients with a low significance (138). 
 
4. INHIBITORS OF SFK ACTIVITY 
 
Several inhibitors of Src family kinase activity have been described. Some of them 
such as PP2 and SU6656 have been used in preclinical trials; whereas Dasatinib is 
used in chronic myeloid leukaemia (CML) and in first phases of clinical trials for solid 
tumours. The three ATP-competitive inhibitors are selective compounds, and therefore, 
they not only inhibit Src family kinase activity, but also, other kinases with similar 
structure of the ATP-binding site. 
 
4.1. Dasatinib 
Dasatinib is a potent biochemical inhibitor of Bcr-Abl and Src kinases but also 
affects Lck, Yes, c-Kit, PDGFRβ and p38 among other kinases. In vivo activity was 
assayed in a xenograft model of chronic myelogenous leukaemia by using nude mice 
implanted with K562. Tumour regressions were observed at multiple dose levels (71). 
Preclinical studies in several solid tumour cell lines, such as prostate, breast and 
glioma have shown that Dasatinib induced an inhibition of cell proliferation, 
invasiveness and metastasis. Sensitivity to Dasatinib was determined by proliferation 
assay of 39 human breast cancer cell lines classified into luminal and basal subtypes. 
A strong correlation between sensitivity to Dasatinib and TNBC basal subtype was 
found. Since Src signalling has an important role in osteoclast activity, Dasatinib could 
prevent osteolytic metastases by inhibition of Src activity. This compound inhibited 
osteoclast proliferation in bone marrow cell culture and diminished serum calcium 
levels in a rat model of bone resorption (5). Furthermore, Zhang et al. shown that the 
bone metastatic activity of MDA-MB-231 bone metastatic derivate cell line was reduced 
by Dasatinib treatment (138). Several phase 1 and 2 studies have been performed 
using Dasatinib in combination with other compounds in solid tumours (5) (Figure 5A).  
 
4.2. PP2 
PP2 has inhibitory effects on SFKs members, including Src and Lck but also on 
other protein kinases, such as RIP2, CK1δ, CSK, Eph-A2 and FGFR1 (6). The 
inhibition of Src family kinases by PP2 reduced liver metastasis in a metastatic model 
consisting of orthotopic implantation of human colon cancer cell line HT29 (89). 
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Furthermore, inhibition of phosphoY418-c-Src by PP2 reduced cell proliferation and 
growth in the cervical cancer cell lines HeLa and SiHa (61) (Figure 5B). 
 
4.3. SU6656 
SU6656 is considered a potent inhibitor of Src family members. However, Bain et al. 
found that it also affected AMPK, BRSK2 and MST2 at a similar degree to Src and Lck 
inhibition. SU6656 inhibited Aurora B and C kinases even more effectively than Src or 
Lck in vitro. CaMKKα, CaMKKβ, CHK2 and SRPK1 were found to be additional targets 
of SU6656 (6). Blake et al. observed that this compound inhibited PDGF- or serum-
stimulated NIH 3T3 cell proliferation (11) (Figure 5C).  
 
 
 
 
 
Figure 5. Structures of SFKs selective inhibitors. The molecular structure of Dasatinib (A), PP2 (B) and 
SU6656 (C) is depicted. Taken from Protein Data Bank. 
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Several aspects of SFKs in breast cancer cells are extensively studied, however 
little is known about the specific role of their catalytic and scaffold functions in the 
process that lead to the metastasis of a highly invasive human breast cancer cell line, 
MDA-MB-231.  
 
The main goal of this Doctoral Thesis is the in vitro characterization of proliferation, 
migration, invasion and transendothelial migration of MDA-MB-231 that depend on Src 
kinase activity or on c-Src by using three different  but complementary approaches: 
inhibition of SFKs enzymatic activity, conditional suppression of c-Src and expression 
of SrcDN (K295M/Y527F). 
 
The specific aims for the elaboration of this Thesis project are:   
 
- To study process dependent on SFKs catalytic activity, by using three different 
selective SFKs inhibitors, Dasatinib, PP2 and SU6656. 
 
- To investigate the role of c-Src, by knocking down its expression using a specific 
short hairpin RNA for c-Src under the tetracycline control in a Tet-On system. 
 
- To determine the functionality of the endogenous members of SFKs expressed in 
MDA-MB-231 cells by conditional expression of SrcDN (K295M/Y527F). 
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1. CELL LINES AND FUNCTIONAL STUDIES 
 
1.1. Reagents 
Stealth RNAi siRNA-Cyr61 (s7244) and scramble siRNA (12935-300) were from 
(Life-Technologies Corporation, Carlsbad, CA, USA). Anti-BrdU FITC-conjugated 
antibody and MatrigelTM were from BD-Biosciences (Bedford, MA, USA). MTT, trypan 
blue, propidium iodide (PI), esiRNA human Rab27a (esiRNA1), SU6656 and 
doxycycline (Doxy) were from Sigma-Aldrich (St. Louis, MO, USA). PP2 was from 
Tocris (Ellisville, MO, USA) and Dasatinib was from LC-Laboratories (Woburn, MA, 
USA). Blasticidin and zeocin were from InvivoGen (IBIAN Technologies, Zaragoza, 
Spain). Tet-Free-FCS (PAA Laboratories GmbH, Passching, Austria). Dharmafect 4 
were from Thermo Scientific (Rockford, IL, USA). 
 
1.2. MDA-MB-231 cell lines 
Three human breast adenocarcinoma cells lines were used to perform experiments, 
MDA-MB-231, MDA-MB-231-Tet-On-shRNA-c-Src and MDA-MB-231-Tet-On-SrcDN 
(K295M/Y527F). 
To generate MDA-MB-231 cell line with conditional expression (Tet-On) of short hairpin 
RNA-c-Src (shRNA-c-Src) or c-Src dominant negative (SrcDN), MDA-MB-231 cells 
were transfected with a vector encoding the Tetracycline repressor (TetR) 
(pcDNA6/TR; Life Technologies) by calcium phosphate method and selected 48 h later 
with 6 µg/ml of blasticidin. Clones were grown and tested for the expression of TetR by 
Western Blot. Clone TR8 was chosen for its maximal expression of TetR and 
transfected with pENTRTM/H1/TO containing shRNA-c-Src sequence #944 (Life 
Technologies) 5’-CACCGCCTCAACGTGAAGCACTACACGAATGTAGTGCTTCACGT 
TGAGC-3’. 
Cells were cultured in medium supplemented with blasticidin and 300 µg/ml of 
zeocin. Selected clones were grown in presence or absence of 2 µg/ml of Doxycycline 
(Doxy) for 72h and tested for expression of c-Src by Western Blot.  
For MDA-MB-231 Tet-On SrcDN cell line generation, clone TR8 was used to 
transfect pcDNA4/TO with SrcDN sequence. After selection with 6 µg/ml of blasticidin 
and 300 µg/ml of zeocin, several clones were grown in medium supplemented or not 
with 1 µg/ml of Doxy for 72h and tested for expression of SrcDN by Western Blot. 
Clones with no basal expression of SrcDN in absence of Doxy that highly induce 
SrcDN upon addition of Doxy were selected, pooled to carry out experiments. 
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1.3. Cell culture 
MDA-MB-231 cell line from the ATCC was maintained in Dulbecco´s Modified 
Eagle’s Medium (DMEM) supplemented with 5% FCS, 2mM glutamine, 100 IU/ml 
penicillin, and 100 µg/ml streptomycin. MDA-MB-231 cells were authenticated by 
means of short tandem repeat (STR) analysis (PowerPlexW 1.2 System; Promega) at 
the Genomic Service of the Institute. MDA-MB-231-Tet-On-shRNA-c-Src and MDA-
MB-231-Tet-On-SrcDN were cultured in the previous medium with 5% Tet-Free-FCS, 3 
µg/ml blasticidin and 100 µg/ml zeocin. Cells were maintained at 37ºC in 5% CO2 and 
splitted at approximately 80-90% confluence. 
SYF cell line (Src, Yes, and Fyn deficient fibroblasts) from ATCC was maintained in 
DMEM supplemented with 5% FCS, 2mM glutamine, 100 IU/ml penicillin, and 100 
µg/ml streptomycin. 
 
1.4. Metabolic activity and proliferation assays 
The effect of the SFKs activity inhibitors on MDA-MB-231 metabolic activity was 
assessed by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay. A graph was generated depicting the metabolic activity as percentage of cells 
treated with each inhibitor at different concentrations respect to the control, DMSO-
treated cells. Exponentially growing cultures were harvested after trypsinization and 
seeded at 1.5 x 104 cells/well in a 96-well plate in 100µl of complete medium for 24h. 
Then, medium was replaced with fresh medium supplemented with DMSO (1:1000, 
Control), Dasatinib (10, 100, 500, 1000 nM), PP2 or SU6656 (1, 5, 25, 50 µM). 
Following 72h treatment, 10 µl of MTT Formazan were added to each well to a final 
concentration of 0.5 mg/ml and incubated at 37 ºC for 4h. Formazan crystals were 
solubilized with 100 µl  of 10% SDS/10 mM HCl at 37 ºC for 2 h and absorbance was 
measured at 570 nm in a VersaMax Elisa microplate reader. 
For MDA-MB-231-Tet-On-shRNA-c-Src and MDA-MB-231-Tet-On-SrcDN cell lines, 
24h after seeding, medium was changed and 2 or 1 µg/ml of Doxy, respectively, were 
added to cultures. Six wells per condition were prepared in three independent 
experiments. 
Cell proliferation was determined by trypan blue exclusion assay. Cells were 
cultured at a density of 1.5 x 105 cells / 35-mm plate, 24 h later medium was changed 
and DMSO, 100 nM Dasatinib, 5 µM PP2 or 5 µM SU6656 were added. For MDA-MB-
231-Tet-On-shRNA-c-Src and MDA-MB-231-Tet-On-SrcDN cells medium was 
supplemented with Doxy (concentrations as above). After 72 h, adherent and detached 
cells were collected, mixed with a 0.4% solution of trypan blue in PBS (1:1) and 
counted with a haemocytometer. 
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1.5. Cell cycle analysis 
Cell cycle studies were performed by flow cytometry using double 
bromodeoxyuridine (BrdU) and propidium iodide (PI) labelling. Cells were plated at a 
density of 1.5 x 106 cells / 60-mm plate in complete medium. Next day cells were pre-
treated for 2 h with DMSO or inhibitors and pulse-labelled with 30 µM of BrdU for 30 
min, washed three times with culture medium and incubated in fresh medium with 
DMSO, Dasatinib, PP2 or SU6656 for 3, 9, 24 and 36 h. Cells at time 0 h were 
collected after washes. At given times, adherent and detached cells were harvested 
and fixed in 1 ml of 70% ethanol in distilled water for at least 1 h at 4 ºC. Then cells 
were incubated at 37 ºC in a solution of 2 ml HCl 2M with 10 µl pepsin buffer (20 mg/ml 
pepsin in 0.1M HCl) for 20 min. After two washes with PBS cells were labelled with 
anti-BrdU conjugated to fluorescein isothiocyanate (FITC) in a solution of 0.5% Tween-
20 / 0.5 % FCS in PBS. Cells were washed with PBS, stained with PI / RNase (20 
µg/ml) and analysed by flow cytometry (FACScan, Becton Dickinson & Company, 
Franklin Lakes, NJ, USA). Background signals were set by BrdU-unlabelled cells 
incubated with anti-BrdU-FITC.  
For cell cycle analysis with PI labelling after 24 h and 72 h treatment with DMSO, 
Dasatinib (100 nM), PP2 (5 µM), SU6656 (5 µM) or ZM447439 (5 µM), detached and 
adherent cells were collected, washed with PBS and fixed in 70% ethanol for at least 1 
h at 4 ºC. Then, PBS was added, cells were pelleted by centrifugation and 
resuspended in 1 ml of PBS, incubated with 20 µg/ml of PI / RNase and analysed by 
flow cytometry. At least 10,000 events per sample were acquired and analysed using 
Cell Quest Pro software (BD). 
 
1.6. Cell migration assays 
Cell migration was analysed by wound healing assay seeding 8 x 105 MDA-MB-231 
cells per 60-mm plate in complete medium. Next day medium was changed and 
supplemented with DMSO or inhibitors (concentrations as before). After 24 h the 
confluent monolayer was scratched with a sterile 200 µl tip and plate was washed twice 
with fresh medium without serum to remove floating cells. Complete medium with 
DMSO, for control, or inhibitors was added to cultures. Same fields were photographed 
at 0 h and 20 h with a Nikon Eclipse TS100 inverted microscope (Nikon Instruments 
Europe B.V., Kingston, Surrey, England) equipped with Olympus DP20 digital camera 
(Olympus Europe GmbH, Hamburg, Germany) at a magnification of 100x.  
For MDA-MB-231-Tet-On-SrcDN cell line, 24h after seeding cells were grown in 
presence or absence of 1 µg/ml of Doxy. Migration assay was performed as above. 
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For MDA-MB-231-Tet-On-shRNA-c-Src, 3.5 x 105 cells/well in 6-well plate were 
seeded in complete medium. Next day, fresh medium with or without 2 µg/ml of Doxy 
was added. After 48 h, the monolayer was scratched, washed twice with serum-free 
medium and complete medium with or without Doxy was replaced. Microphotographs 
were taken at 0 h and 20 h with a Microscope Cell Observer Z1 system (Carl Zeiss 
MicroImaging GmbH, Jena, Germany) equipped with a controlled environment 
chamber (37°C and 5% CO2) and Camera Cascade 1k, under 4x objective.   
Migration was quantified using Wound-healing tool of ImageJ. Each value 
represents the percentage of wound-healing area at 20 h respect to 0 h in three 
independent experiments. 
Random migration assay was carried out by seeding MDA-MB-231-Tet-On-shRNA-
c-Src cells at a low density (5 x 104 cells) in a 6-well plate. After 48 h of Doxy-treatment, 
cells were washed with serum-free medium and placed in 2% FBS medium. Three 
fields per well (three wells per condition) were photographed with the Microscope Cell 
Observer with a 10x objective, every 15 min for 22 h. Directionality, mean velocity, 
accumulated and Euclidean distances travelled were quantified from at least 63 cells 
per condition (7 per field ) by using ImageJ. The experiment was repeated three times. 
 
1.7. Transendothelial migration assay 
MDA-MB-231-Tet-On-shRNA-c-Src cells were seeded in complete medium at 4.5 x 
105 cells / 60-mm plate. At the same time, 5 x 104 human umbilical vein endothelial 
cells (HUVEC) in 120 µl of EGM medium (Lonza) were added over 0.2 % gelatin-
coated cell culture inserts for 24-well plate (8 µm-pore PET membranes) (Falcon, BD 
Biosciences). Next day shRNA-c-Src cells were treated with or without 2 µg/ml of Doxy. 
After 48h treatment, 5 x 104 shRNA-c-Src cells in 120 µl serum-free DMEM were 
placed on the top of HUVEC monolayer. The lower chamber was filled with 600µl of 
20% FBS-supplemented medium. As control, in order to test the spontaneous 
migration of HUVEC cells, two HUVEC-coated filters were placed in the same 
conditions, without seeding shRNA-cSrc cells. After 22 h, transmigrated cells were 
detached from the bottom of the filter and counted in a haemocytometer. The number 
of Doxy-treated transmigrated cells was expressed as the percentage respect to 
control transmigrated cells (100%). c-Src suppression was determined by Western blot 
before plating shRNA-c-Src cells over HUVEC monolayer and at 22 h.  
 
1.8. Invasiveness assay 
Invasion assay of MDA-MB-231 cells was performed in cell culture inserts of 8 µm 
pore in a 24-well plate. The chamber insert was coated with 100 µl of Matrigel diluted in 
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serum-free medium at a final concentration of 250 μg/ml and allowed to gelify overnight 
at room temperature. Next day, 5 x 104 cells were seeded in 200 μl of complete 
medium on the top of each Matrigel-coated filter. Cells were allowed to attach and then 
medium was replaced with fresh serum-free medium containing DMSO or inhibitors. 
Lower chamber was filled with 300 μl of medium supplemented with 10% FBS and 
DMSO or inhibitors. After 24 h, the cells on the top of inserts were removed and 
invasive cells attached to the bottom were fixed in methanol and stained with 
DAPI/PBS (10 µg/ml), mounted on slides with ProLong antifade-reagent. 
Photomicrographs of at least 4 fields/insert were taken with a Plan 20x/0.50 objective 
using Eclipse 90i fluorescence microscope equipped with Digital Sight DS-Qi1 camera 
and NIS-Elements BR imaging software (Nikon). DAPI-stained nuclei were counted. 
Four assays were made in triplicate. 
MDA-MB-231-Tet-On-shRNA-c-Src and MDA-MB-231-Tet-On-SrcDN cells were 
cultured at a concentration of 5 x 105 / 60-mm plate. Next day medium was changed by 
fresh medium supplemented with Doxy (2 or 1 µg/ml of Doxy, respectively). After 48 h, 
cells were detached with trypsin and assay was performed as previously described for 
MDA-MB-231 cell line, in presence or absence of Doxy. 
 
1.9. Soft-agar colony formation assays 
The anchorage-independent growth of MDA-MB-231-Tet-On-shRNA-c-Src cell line 
was evaluated by soft-agar colony formation assay. Three milliliters of 0.5% agar in 
DMEM 10% FCS with or without 2 µg/ml of Doxy was solidified in the bottom of 60-mm 
plates. Exponentially growing cells were resuspended in a prewarmed solution of 0.3 % 
agarose in complete medium, with or without Doxy, and seeding at a density of 1 x 105 
cells / agar precoated dish. Cells were re-fed every 3 days with complete medium (300 
μl / plate) with or without Doxy. After 20 days of growth, plates were stained with 0.5 ml 
of 0.005 % crystal violet in distilled water for at least 1 h. Colonies measuring more 
than 0.1 mm were counted under a Nikon Eclipse TS100 inverted microscope. Two 
independent experiments were performed in triplicate. 
 
1.10. Three-dimensional culture assay 
For three-dimensional (3D) analysis of morphology, 3D embedded assay was 
performed as previously described (66). Cell culture dishes (24-well plates) were 
precoated with 50 μl of undiluted growth factor-reduced Matrigel (10 mg/ml) per well 
and allow to gel for 30 min at 37 °C. To analyse the effects of SFKs selective inhibitors 
on 3D cell growth, 1 x 104 cells per well were resuspended in 300 μl of complete 
medium/Matrigel (1:3) containing DMSO (control), Dasatinib (100 nM), PP2 (5 μM) or 
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SU6656 (5 μM) seeded over the gelified coat Matrigel and incubated for at least 30 min 
at 37 °C. Then, 500 μl of complete medium containing DMSO or SFKs selective 
inhibitors was added to the cultures and changed every 2–3 days for 21 days. To 
assess the effects of the inhibitors on MDA-MB-231 spheres already formed, 
compounds were added after 21st day of growth and maintained for additional 7 days. 
Treatments were performed in triplicate and assays were repeated twice. 
Representative fields were photographed at 10x magnification using the Nikon Eclipse 
TS100 inverted microscope equipped with Olympus DP20 digital. 
 
1.11. Mammosphere formation assay 
Cell suspensions of MDA-MB-231-Tet-On-shRNA-c-Src cell line were plated at low 
density of 1 x 103 cells/ml in ultra-low attachment 6-well plates (Falcon, Corning Life 
Sciences, Tewksbury MA, USA) in mammosphere culture medium: DMEM/F12 
medium containing B27 (1:50; Life Technologies), 20 ng/ml EGF and bFGF 
(PeproTech EC Ltd., London, UK), 5 μg/ml insulin, 1μg/ml hydrocortisone (Sigma). To 
exclude sphere formation due to cell aggregation (47), mammosphere assay was also 
performed by plating cells in 96-well ultralow attachment plates at very low density (10 
cells/100μl/well). To examine the effect of Src suppression on mammosphere 
formation, 2 μg/ml of Doxy was added in the growth medium at seeding and every 3 
days. After 20 days, mammospheres were manually counted using the Nikon-Eclipse 
TS100 under 4x magnification. Sphere forming efficiency (SFE) was calculated as 
number of sphere-like structures (diameter ≥ 50 μm) formed in 20 days divided by 
number of seeded cells and expressed as percentages of the means ±SD.  
 
1.12. Time-lapse video microscopy 
MDA-MB-231 cells were seeded in complete medium in 35 mm µ-dishes (1 x 105 
cells / dish). After 24h, cells were treated with DMSO (Control) or SU6656 (5 µM). 
Images were taken every 15 min, 3h after inhibitor addition until 20 h. Live cell imaging 
was obtained with a 20x Plan Apochromat objective, using microscope Cell Observer 
Z1 system. Time-lapse movies were formatted using imaging software AxioVision 4.8 
(Zeiss). 
 
1.13. Transient transfection of siRNA-Cyr61 and esiRNA-Rab27a 
Silencing of Cyr61 or Rab27a was achieved using transient transfection of siRNA-
Cyr61 (s7244) or esiRNA-Rab27a. MDA-MB-231 cells (1 x 105 cells/well) were seeded 
in 2 ml of complete media without antibiotics in a 6-well plate. Next day, transient 
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transfection was performed. Briefly, 5 µl of Dharmafect 4 were diluted in 195 µl of 
DMEM with L-glutamine. In another tube, siRNA was diluted with DMEM with L-
glutamine to a final concentration of 20 nM for siRNA-Cyr61, 50 nM for esiRNA-
Rab27a or and 20/50 nM for scramble siRNA (Life Technologies), respectively. After 5 
min incubation at room temperature, both mixes were incubated together for 20 min. 
Then, medium from cells was removed and replaced with 1.6 ml medium without 
antibiotics and 400 µl of appropriate transfection mix were added to each well. Cells 
were incubated at 37 ºC for 8 h and then medium was replaced. After 40 h of 
transfection, cells were detached with trypsin and used for invasion, transendothelial 
migration or Western blot (72h) assays, as previously described. When esiRNA-
Rab27a was employed, medium was changed after 72h and cells were then 
maintained 24h in serum-free media. Secretome and total cell extracts were used for 
Western blot analyses. 
 
1.14. Statistical analysis 
All results are expressed as mean ± standard deviation (SD) of at least three 
independent experiments. Parametric bilateral Student t-test was used for statistical 
analyses. Two-sided p-values less than 0.05 were considered statistically significant. 
 
2. PROTEIN-BASED ASSAYS 
 
2.1. Reagents  
Anti-c-Src 327 was a gift of Joan S. Brugge (Harvard University). Anti-Tet-repressor 
(Mobitec, Göttingen, Germany). Anti-Fak (A17),  anti-p120-catenin (S-19), anti-c-Myc 
(N262), anti-Cyr61 (sc-13100), anti-Oct3-4 (C-20) and anti-cyclin D1 (H-295) were from 
Santa Cruz Biotechnology (Santa Cruz, TX, USA). Anti-Cis-Golgi-gp74 25H8 was a gift 
of Ignacio Sandoval (Centro de Biología Molecular Severo Ochoa, Madrid) (4). Anti-
Rab27a polyclonal antibody was a gift of Peter van der Sluijs (University Medical 
Center Utrecht) (91). Anti-CD63 (63PU-S, Inmuno-Step, Salamanca, Spain; 
Calbiochem OP171, Merck-Millipore), antibodies to MMP-2 (AB6003), MMP-9 
(AB19016), anti-pS10-histone H3, phosphotyrosine 4G10, anti-avian Src mouse mAb 
clone EC10 and Nanog (AB9220) were from Millipore (Merck Millipore Corporation, 
Billerica, MA, USA). Anti-MMP-7 (AP6212a) was from Abgent (San Diego, CA, USA). 
Anti-pY925-Fak, anti-pS473-Akt and anti-pY118-paxillin were from Cell Signaling 
Technologies (Danvers, MA, USA). Anti-aurora B and anti-histone H3 were from 
ABCAM (Cambridge, UK). Anti-paxillin, anti-p130CAS, anti-caveolin, anti-pY14-
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caveolin, anti-β-catenin and anti-p27Kip1 were from BD-Biosciences. Anti-Sox2 was 
from Neuromics (Edina, MN, USA). Anti-pY397-Fak, anti-pY418-Src, secondary 
horseradish peroxidase-conjugated antibodies, goat-anti-mouse IgG Alexa-Fluor 546, 
goat-anti-rabbit IgG Alexa-Fluor 488, DAPI (D1306), ProLong anti-fade-reagent were 
from Life-Technologies Corporation. Purified histone H3 was from Roche Applied 
Science (Indianapolis, IN, USA). Acrylamide/Bis-acrylamide (29:1), SDS and 
ammonium persulfate were from Bio-Rad Laboratories (Hercules, CA, USA). ECL was 
from GE Healthcare Biosciences (Pittsburgh, PA, USA). BCA protein assay was from 
Thermo Scientific. 
 
2.2. Protein extraction and quantification 
Subconfluent cell cultures from three 60-mm dishes were washed twice in ice-cold 
PBS and lysed in ice-cold lysis buffer (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 30 mM 
sodium pyrophosphate, 5 mM EDTA, 5 mM EGTA, 1% Triton X100, 50 mM NaF, 0.1 % 
SDS, 0.1 mM Na3VO4, 1mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 mM 
iodacetamide, 1 mM ortho-phenantroline). The cell lysates from three plates for each 
condition were pooled. The supernatants from a centrifugation of 15,000 xg for 30 min 
at 4 ºC were collected and protein concentration was determined by BCA protein assay 
in a microreader plate. Extracts were compensated for differences in protein 
concentration with lysis buffer, boiled in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 
5% β-mercaptoethanol, 2% SDS, 10% glycerol) and stored at -20 ºC until further use. 
 
2.3. Western blotting 
Equal amounts of protein (30 μg) were separated by SDS-PAGE and 
electrotransferred to a polyvinylidene difluoride (PVDF) membrane for 45 min at 2.5 
mA/cm2. Nonspecific binding on the PVDF filters was minimized by blocking with 5% 
non-fat dry milk in TBST (10 mM Tris-HCl, pH 7.4, 0.1% Tween-20), or 5% bovine 
serum albumin in TBST for anti-phosphoproteins immunodetection for 1 h at room 
temperature. Membranes were then incubated with specific primary antibodies in 
blocking buffer overnight at 4 ºC. After three washes with TBST, filters were incubated 
with suitable secondary antibody conjugated to horseradish peroxidase for 1 h at room 
temperature. Membranes were washed three times with TBST and proteins were 
detected with enhanced chemiluminescence reagent (ECL). X-ray films were scanned 
and signal was measured by densitometry using ImageJ program. Protein expression 
was determined relative to loading control signal; control condition (DMSO or Doxy 
untreated cells) was arbitrarily assigned a value of 1. 
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2.4. Aurora B kinase activity assay 
Exponentially growing cultures were lysed in buffer B (50 mM Hepes, pH 8, 600 
mM KCl, 0.5% Nonidet P40, 1 mM Na3VO4, 1mM DTT, 0.1 mM protease inhibitors) at  
4 ºC. Aurora B kinase was immunoprecipitated from total cell extracts, as described 
previously (Tardaguila et al. (117)). Immune-complexes were incubated with 1 µg of 
histone H3 for 30 min at 37 ºC in kinase assay buffer (20 mM Hepes, pH 7.4, 150 mM 
KCl, 5 mM MnCl2, 5 mM NaF, 1 mM DTT, 30 µM cold ATP) in presence or absence of 
1 µM SU6656. pS10-H3, H3 and Aurora B kinase expression were determined by 
Western blot. 
 
2.5. Immunofluorescence and confocal microscopy 
For immunofluorescence studies, MDA-MB-231 cells seeded on sterile coverslips 
were treated for 24 h with DMSO or inhibitors, fixed with 3.7% paraformaldehyde in 
PBS for 10 min at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 
5 min at room temperature and blocked for 30 min with 1% BSA in PBS. Coverslips 
were incubating at 37 ºC for 1h with TRITC-labelled phalloidin (1:200 in PBS-1% BSA) 
or with primary antibodies, anti-α-tubulin (1:50) and anti-phosphohistone H3 (1:200). 
Following washes with PBS, cells were probed with Alexa Fluor 488 goat anti-mouse or 
Alexa Fluor 546 goat anti-rabbit, secondary antibodies (1:200) for 1 h at 37 ºC. 
DAPI/PBS (10 µg/ml) was used for 10 min at 37 ºC to counterstain the cells, after 
washing with PBS. Then coverslips were mounted on slides with ProLong anti-fade 
reagent. Samples were photographed with a Plan Apochromat 60x/1.40 objective using 
a Nikon Eclipse 90i fluorescence microscope equipped with Digital Sight DS-Qi1 
camera and NIS-Elements BR imaging software (Nikon). 
 
For confocal microscopy assays, MDA-MB-231 cells 24 h-treated with or without 
inhibitors, as well as, MDA-MB-231-Tet-On-shRNA-c-Src cells, treated or not with Doxy 
for 72 h, were fixed and permeabilized as above, blocked with 5% normal goat 
serum/PBS and washed with PBS-1% BSA. MDA-MB-231 cells were incubated with 
anti-pY118-paxillin (1:50), anti-pY925-Fak (1:50), anti-β-catenin (1:100) or anti-p120-
catenin (1:100). MDA-MB-231-Tet-On-shRNA-c-Src cells were incubated with the 
primary antibodies rabbit polyclonal anti-Cyr61, anti-IGFBP4 in combination with 
mouse monoclonal anti-25H8 or anti-CD63 (1:100). Coverslips were washed with PBS 
and then incubated with secondary antibodies diluted 1:400 in 5% normal goat 
serum/PBS. Samples were mounted after DAPI/PBS counterstaining. Images were 
acquired using an inverted Zeiss LSM 710 laser-scanning microscope with a Plan 
Apochromat 60x/1.40 objective. Sequential scanning mode was used to avoid crosstalk 
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between channels. Z-optical stacks with 0.6 µm intervals through the cell Z-axis were 
recorded. Images were processed with ZEN 2009 software (Zeiss) and Adobe 
Photoshop CS5 (Adobe Systems In., USA). 
 
2.6. Secretome analysis 
2.6.1. Secretome fractionation 
Cultures of MDA-MB-231-shRNA-c-Src were grown for 48h in the absence or 
presence of Doxy (2 µg/ml) in complete media. Cells were then washed three times 
with serum- and phenol red-free DMEM and then incubated for additional 24h in this 
medium in absence or presence of Doxy. Conditioned media from control or Doxy-
treated shRNA-c-Src cells were used to prepare total secretome or soluble and 
exosomal fractions of secretome by differential centrifugation, as described (118). 
Briefly, the culture media was spin down at 300 xg for 10 min and supernatant was 
then centrifuged at 2,000 xg 10 min to remove alive and dead cells obtaining total 
secretome. Total secretoma from MDA-MB-231-Tet-On-SrcDN cells was prepared as 
above, growing cells with or without 1 µg/ml of Doxy. In order to prepare soluble 
secretome and exosomal fraction, additional centrifugation steps were performed at 
10,000 xg for 30 min and 100,000 xg for 70 min. The proteins from supernatant of 
100,000 xg, were concentrated by methanol/chloroform precipitation (soluble 
secretome). Microvesicle pellet was resuspended in PBS-5mM EDTA for Western blot 
analyses (Figure 1). 
 
 
 
 
 
 
Figure 6. Outline of differential ultracentrifugation of secretome to isolate exosomes. Adapted from 
Thery et al. 
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2.6.2. Secretome protein digestion and iTRAQ-4-plex® labelling  
Total secretome from MDA-MB-231-Tet-On-shRNA-c-Src was obtained from 
culture media as described above, and the pellet was discarded. For digestion, 20 µg 
of protein from each secretome condition (-/+ Doxy) were precipitated with 
methanol/chloroform. Twenty micrograms of protein from each condition were reduced 
with TCEP [Tris(2-carboxyethyl)phosphine], alkylated with MMTS (methyl 
methanethiosulfonate), digested with trypsin and labelled with iTRAQ reagent. Samples 
labelled with iTRAQ tags 116 and 117 were used for control conditions and 114 and 
115 for Doxy-treated replicates. After peptide labelling with iTRAQ reagents, the four 
reaction mixtures of each experiment were then combined into a single tube and 
labelling reaction stopped by evaporation in a Speed Vac. Each digested, labelled and 
pooled samples were desalted using Sep-Pak C18 cartridges (Waters), vacuum 
concentrated and reconstituted with 0.1% heptafluorobutyric acid (HFBA). 
 
2.6.3. Secretome protein separation and analysis by RP-LC-MALDI TOF/TOF 
MS 
The resulting peptide mixtures were separated by Tempo nano multidimensional 
liquid chromatography coupled to mass spectrometry for protein identification (AB 
SCIEX, Foster City, CA, USA). After separation in nanoMDLC HPLC, peptides were 
then eluted onto an Onyx monolith C18 column (150mm x 0.1mm i.d.) (Phenomenex, 
Aschaffenburg, Germany). A 1.5 μl/min flow rate of 3 mg/ml α-cyano-4-hidro-cinnamic 
acid MALDI matrix diluted in 70% acetonitrile and 0.1% TFA aqueous solution, were 
mixed post-column with the eluted peptides. Spots were deposited on the MALDI-plate 
(Opti-TOF™ LC MALDI Insert, AB SCIEX, Foster City, CA, USA) by a fraction collector 
Suncollect (SunChrom GmbH, Friedrichsdorf, Germany). A MALDI TOF/TOF 4800 (AB 
SCIEX) mass spectrometer was used for acquisition and processing of the data. MS 
data from the spots were acquired in positive reflector ion mode in the mass range of 
800-3500m/z by accumulation of 1200 laser shots. MS/MS spectra were generated by 
2kV collisions with air. Maximal 2000 laser shots were accumulated for MS/MS spectra.  
Raw files containing a peak list of the precursors and fragment ions were filtered 
and exported with the ABI-Extractor tool (Peaks-Bioinformatics Solutions, Waterloo, 
Canada). Protein identification and quantitation on each of the two data sets were done 
by using MASCOT v2.3.01 (Matrix Science, London, UK) and Phenyx v2.6 (GeneBio, 
Geneva, Switzerland) search engines. The searches were performed against the 
UniProtKB/Swiss-Prot human database (40,478 sequences; 22,568,758 residues) to 
estimate the false discovery rate (FDR) below 1%, which boosted the reliability of the 
data. The confidence interval for protein identification was set to ≥ 95% (p<0.05) and 
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only peptides with an individual ion score above the 1% FDR score threshold were 
considered correctly identified. Differential expression of proteins between controls and 
Doxy-treated samples was determined by calculating the weighted average ratios of 
the peptides for each identified protein. Only proteins having at least two quantitated 
peptides were considered in the quantitation. 
 
3. GENE EXPRESSION PROFILING 
 
3.1. RNA extraction and quantification 
MDA-MB-231 or MDA-MB-231-Tet-On-shRNA-c-Src cells were treated for 72 h with 
inhibitors (100 nM Dasatinib, 5 µM PP2 or SU6656) or with 2 µg/ml Doxy, respectively. 
Total RNA from cultures at 70% confluence was extracted using RNeasy kit (Qiagen, 
Hilden, Germany), following manufacturer’s instructions, from three independent 
experiments made in triplicate. RNA quantity and quality was assessed by NanoDrop 
and using the RNA 6000 Nano Assay kit on an Agilent 2100 Bioanalyser (Agilent 
Technologies, Santa Clara, CA, USA). RNA samples with an integrity value higher than 
or equal to 8 from each treatment per experiment were pooled. cDNA was synthesized 
using random octamer primers with kit High Capacity cDNA Reverse Transcription 
(Applied Biosystems, Life Technologies) following manufacturer’s instructions. 
 
3.2. Real time quantitative PCR analysis (qRT-PCR) of c-Src mRNA and 
gene expression analysis 
c-Src mRNA expression was determined by using TaqMan probe for human c-Src 
(Hs01082246_m1), TBP (TATA-box binding protein) was used as endogenous control 
(Life Technologies). For CCN1 (Cyr61) qRT-PCR was carried out using SYBR Green 
Master Mix (Life Technologies) according to manufacturer’s instructions. For Cyr61 the 
primers 5’-TCCAGCCCAACTGTAAACATCA-3’ and 5’-
GGACACAGAGGAATGCAGCC-3’  were used and for endogenous control, GAPDH, 
5’-GTGAAGGTCGGAGTCAACG-3’ and 5’-TGAGGTCAATGAAGGGGTC-3’, as 
described previously (136). Gene expression was then calculated as the difference in 
threshold cycle (∆Ct) between the target gene and TBP and GAPDH respectively; ∆∆Ct 
was the difference between the ∆Ct values of the test sample and that of the control. 
Relative expression of target genes was calculated as 2-∆∆Ct. 
 
Ten micrograms of total RNA from DMSO or inhibitors-treated cells were used to 
prepare probes, then targets were hybridized to Agilent Sure Print G3 Human GE 
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8x60k Microarray (Santa Clara, USA) following manufacturer’s instructions. Differential 
expression analysis was performed using R platform for statistical analysis (R 
Foundation for Statistical Computing, Vienna) and several packages from the 
Bioconductor Project (http://www.bioconductor.org/). The raw data were imported into 
R and preprocessed using half method for background correction and the quantile 
method for normalization. Probes with expression level below the detection control 
probe in all samples were removed. To identify differentially expressed genes, we used 
the limma package. Correction for multiple hypotheses testing was accomplished by 
using Benjamini and Hochberg False Discovery Rate (FDR) adjustment (8). Genes 
were selected as differentially expressed with an adjusted P value ≤ 0.05. Hierarchical 
clustering analysis of gene expression profiles was carried out using the complete 
linkage method.  
 
3.3. Gene Set Enrichment Analysis (GSEA) 
Gene Set Enrichment Analysis (110) was applied to define gene sets based on 
prior biological knowledge about biochemical pathways using Biocarta, KEGG and 
Reactome databases and based on Src gene set previously reported (9). Genes were 
ranked based on limma moderate t statistic. After Kolmogorov-Smirnov testing, those 
gene sets showing FDR ≤  0.05, were considered significantly enriched among 
compared treatments. 
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1. GENERATION OF MDA-MB-231-Tet-On-shRNA-c-Src AND MDA-MB-
231-Tet-On-SrcDN (K295M/Y527F) 
 
Clones from MDA-MB-231-Tet-On-shRNA-c-Src cells were analysed by Western 
Blot for reduction of c-Src expression upon induction of shRNA-c-Src by addition of 
Doxy (2 µg/ml, 72h) to cultures. Those clones with a significant reduction of c-Src 
expression were chosen and pooled. Pool #11 was tested for c-Src mRNA and protein 
levels in absence or presence of distinct concentrations of Doxy (data not shown) and 
at different time-points (0 , 14 , 24, 48 and 72 h). In view of the results, pool #11 was 
used for the experiments, that were usually performed at 2 µg/ml Doxy for 72 h (Figure 
7A and 7B). 
The generation of MDA-MB-231-Tet-On-SrcDN gave rise to several clones, that 
were tested for SrcDN expression by Western Blot. The clones with SrcDN expression 
upon induction with 1 µg/ml of Doxy for 72h and absence of SrcDN expression without 
Doxy were selected and pooled. Pool #20, was selected by its expression in presence 
of Doxy and absence without Doxy (Figure 7C). 
 
 
 
 
 
 
 
Figure 7. Analysis of c-Src and SrcDN expression in MDA-MB-231. (A) Relative c-Src mRNA levels 
after 2 μg/ml of Doxy treatment for the indicated times. (B) Whole-cell lysates treated with Doxy for the 
indicated times were analysed by SDS-PAGE and immunoblotting using anti-c-Src (mAb 327) and anti-β-
actin, as loading control. (C) The expression of SrcDN and β-actin were detected by Western Blot in cell 
lysates of MDA-MB-231-Tet-On-SrcDN cells treated or untreated with 1 μg/ml of Doxy (72 h) using the 
specific anti-avian Src mAb (EC10). Representative blots of three experiments are shown. 
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2. EFFECTS OF KINASE ACTIVITY INHIBITION, c-Src SUPPRESSION AND 
SrcDN EXPRESSION ON PROLIFERATION, CELL CYCLE AND 
MORPHOLOGY 
 
SFKs are involved in survival and proliferation in different cancer cells, including 
breast cancer (111). In this context, we previously showed that c-Src participated in the 
control of G1-S transition in the non-metastatic breast cancer cell line, MCF7 (41). 
Therefore, we performed in vitro proliferation assays by trypan blue exclusion method, 
as well as by MTT to measure the metabolic activity, in MDA-MB-231 with inhibition of 
Src family kinase activity, depletion of c-Src or SrcDN expression. Since inhibitors of 
SFKs enzymatic activity are not fully specific and can affect other tyrosine kinases, we 
used three SFKs selective inhibitors, Dasatinib, PP2 and SU6656. It allows to 
distinguish the effects caused by Src kinases activity from those produce on additional 
kinases activity. 
 
2.1. Anti-proliferative effects of SFKs kinase activity inhibition with 
Dasatinib, PP2 and SU6656  
To determine concentrations of the selective inhibitors to be used in this study, we 
examined the metabolic effects of Dasatinib, PP2 and SU6656 on MDA-MB-231 cells 
for 72h by MTT assay. As shown in Figure 8A at 100 nM Dasatinib (Das) and 5 µM 
PP2 and SU6656 (SU) the mitochondrial conversion of the tetrazolium salt, MTT, to its 
formazan product was reduced to about 55% with respect to control-treated cells 
(DMSO). At these concentrations of the selective inhibitors, Src activity was decreased 
as revealed by Western blot analysis of pY416-Src. Dasatinib reduced 90% the extent 
of Src phosphorylation at Y416, PP2 70% and SU6656 40%, approximately (Figure 8B).  
MTT assay for shRNA-c-Src or SrcDN expression induced by Doxy (2 µg/ml or 1 
µg/ml, respectively) for 72 h revealed no significant differences in metabolic activity 
(Figures 8C and 8D). Cell viability was studied by trypan blue exclusion test after 72h 
treatment at Doxy concentrations previously tested. Dasatinib and PP2 reduced 
proliferation by about 30% and SU6656 nearly 70% (Figure 8G). Furthermore, the 
number of cells positive for trypan blue was lower than 5% (data not shown), 
suggesting no cytotoxic effects at these concentrations. In contrast, shRNA-c-Src or 
SrcDN expression had no significant effect on cell proliferation (Figures 8E and 8F). 
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2.2. Changes in cell cycle distribution caused by SFKs inhibitors 
Since cell viability was reduced by inhibition of SFKs catalytic activity, we 
performed a BrdU pulse-chase assay with PI labelling to determine alterations in cell 
cycle. The FACS analyses revealed that treatment with Dasatinib or PP2 induced 
accumulation of cells in G1 and reduced the fraction of cells in S and G2/M phases, as 
compared to control-treated cells. In contrast, the analysis of SU6656-treated cells 
showed an altered cell cycle, with a progressive decrease in G1 cells and increase in 
G2/M cells until 24 h. At this time appeared a new cell population with >4N DNA 
content that progressively increased with time (Figure 9A). 
To confirm these results, PI labelling of cells treated with inhibitors or DMSO 
(control) at a longer time (72 h) was performed. Dasatinib and PP2 treated cells shown 
a higher proportion of G1 cells compared to 38 h treatment. However, the >4N 
compartment remained unaltered compared to control cells. In SU6656 treated cells, 
G1 and S fractions were reduced and the fraction of cells in G2/M phases was 
increased, whereas the polyploid population was the most represented, about 60-70% 
(Figure 9B). Consistently, this compound did not inhibit DNA duplication, but it probably 
blocked cell cycle completion, according to the strong reduction (about 70 %) in the 
number of cells determined by trypan blue assay respect to control cells (Figure 8G). 
 The percentage of cells present in the subG1 fraction was no significant in the 
treatment with the inhibitors compared to control. Furthermore, no PARP degradation 
was observed (data not shown), suggesting that these compounds, under these 
experimental conditions, did not induce apoptosis. 
Moreover, the increase of p27Kip1 and the decrease of c-Myc expression provided 
further evidence for the G1 arrest of Dasatinib and PP2 treated cells. No modifications 
in p27Kip1 or  c-Myc levels were observed in cells treated with SU6656 compared to 
control cells (Figure 9C).  
Since the SFKs inhibitors Dasatinib, PP2 and SU6656 are able to inhibit other 
targets, we wondered whether the effects on cell cycle could be due to the inhibition of 
additional kinases. To investigate this hypothesis, we performed a PI labelling to 
analyse cell cycle of SYF cells, fibroblasts derived from triple c-src, yes and fyn 
knockout mice (60). Analyses of cell cycle at 24 h showed no significant differences in 
G1 fraction between Dasatinib, PP2 or DMSO (control) treated cells. However, SU6656 
provoked cell cycle alterations similar to those observed in MDA-MB-231 cells 
(reduction in G1 and S phases and increase in G2/M and >4N compartments) (Figure 
9D). 
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2.3. Effects of SU6656 on cell cycle: Aurora B kinase 
Since SU6656 is a kinase inhibitor, we hypothesized that a kinase involved in 
regulation of mitosis could be affected. Polyploidy and enlarged cell size phenomena 
observed in MDA-MB-231 were similar to those detected by Giet et al. in distinct 
human tumour cell lines by inhibiting of an enzyme that belongs to the chromosome 
passenger protein family, Aurora B kinase (40). Besides, SU6656 has been described 
as an Aurora B kinase inhibitor in vitro (6,63). Therefore, we used a selective inhibitor 
of Aurora B kinase, ZM447439 (31), to compare its effects on cell cycle profile with 
those provoked by SU6656, used at the same concentration (5 μM). PI labelling after 
24 h treatment with SU6656 or ZM447439 showed a similar pattern; a reduction in the 
percentage of cells in G1 and S phases and an increase in G2/M and >4N 
compartments compare to control cells (Figure 10A). 
Figure 9. Effects of SFKs inhibitors on cell cycle of MDA-MB-231 and SYF cells. (A) Cell cycle 
analyses by pulse/chase BrdU and PI labelling of MDA-MB-231 cells treated with DMSO (control), 
Dasatinib (100 nM), PP2 (5 μM) and SU6656 (5 μM). Results represent the average ±SD of four 
independent experiments. (B) Cell cycle of MDA-MB-231 by PI labelling after 72 h inhibitors treatment. (C) 
Whole-cell lysates from MDA-MB-231 cells treated 24 h with DMSO (C), Das, PP2 or SU were probed for 
p27Kip1 and c-Myc. Membranes were reblotted for α-tubulin and β-actin, respectively, as loading controls. 
Blots are representative of three independent experiments. (D) Cell cycle analyses after PI labelling of SYF 
cells treated 24 h with DMSO (C), Das, PP2 or SU (concentrations as above).  
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A canonical substrate of Aurora B kinase is serine-10 of histone H3 
(31,40,100,117), then we analysed the expression of pS10-H3 by Western blot in 
subconfluent cultures treated with DMSO (control), ZM447439 (positive control) and 
SU6656 for 24 h. A reduction in pS10-H3 levels was observed in both SU6656 and 
ZM447439 treated cells (Figure 10B). To confirm that SU6656 directly inhibited Aurora 
B kinase in MDA-MB-231 we performed an in vitro kinase assay. Aurora B kinase was 
immunoprecipitated from cultures 24 h-treated with DMSO or SU6656 and incubated 
with 1 µg of purified histone H3 in kinase assay buffer. A strongly reduction in pS10-H3 
was observed in SU6656 immune-complexes (Figure 10C). To further confirm these 
results DMSO, SU6656 and ZM447439 treated cells (24 h) were analysed under 
fluorescence microscope after staining with DAPI, α-tubulin and pS10-H3. Analysis of 
mitotic cells treated with SU6656 or ZM447439 shown cells with multiple spindle poles 
and a decreased expression of pS10-H3, compared to control (Figure 10D).  
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2.4. Effects on 3D growth pattern caused by SFKs activity inhibition 
Three-dimensional (3D) cultures better mimic the tumour extracellular 
microenviroment to study tumour cell progression. Given the effects observed on cell 
proliferation in two-dimensional conditions, we studied the effects of SFKs inhibition on 
3D cultures. MDA-MB-231 cells were growth embedded in Matrigel in presence or 
absence of the selective inhibitors. After 21 day-growth in the presence of Dasatinib or 
PP2, colonies size decreased respect to DMSO-treated cells (control). However, 
SU6656 prevented colony formation inducing the appearance of enlarged cells (Figure 
11A). We also tested if these compounds could affect already-formed spheres. After 
21-day growth, addition of PP2 or SU6656 for further 7 days provoked no effects, 
however Dasatinib reduced colony size (Figure 11B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Comparative effects of SU6656 and ZM447439 in MDA-MB-231 cells. (A) Cell cycle 
analyses by PI labelling after 24 h treated with DMSO (control), SU6656 (5 μM) and ZM447439 (5 μM). (B) 
Immunoblot analyses of histone H3 and its phosphorylation in S10 from cells treated with DMSO (C), SU or 
ZM for 24 h at concentrations as above. (C) Aurora B kinase was immunoprecipitated from cultures treated 
with DMSO (C) or SU (5 μM) for 24 h. Immune-complexes were incubated with histone H3 in the presence 
or absence of SU6656 (1 μM) and ATP; the phosphorylation of S10-H3 was determined by Western blot. 
(D) Representative immunofluorescence micrographs of mitotic MDA-MB-231 cells. Control and SU- or 
ZM-treated cells for 24 h were labelled for DNA (DAPI, blue), microtubules (anti α-tubulin, green) and 
pS10-histone H3 (anti-pS10-H3, red). 
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2.5. Alteration of cell morphology caused by inhibition of SFKs 
Analysis of cell morphology by phase contrast microscopy showed that the 
inhibition of Src kinase activity for 24 h by Dasatinib produced rounded cells, 
meanwhile PP2 generated spindle cells and SU66565 increased cell size (Figure 12A). 
However, c-Src suppression or SrcDN expression did not altered cell phenotype 
(Figure 12B and 12C).  
 
Figure 11. 3D structures of MDA-MB-231 after SFKs inhibition. (A) Representative photos from 
contrast-phase microscopy shown colonies at 7, 14 and 21 days growth embedded in Matrigel in presence 
of DMSO, Das (100 nM), PP2 or SU6656 (5 μM). (B) Effects of 7 day-inhibitor treatments after 21 days of 
colonies growth. Scale bar, 10 μm. 
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To further characterize these changes, MDA-MB-231 grown as previously, were 
labelled with α-tubulin and DAPI and observed under fluorescence microscope. 
Dasatinib-treated cells showed partially collapsed microtubule structure defining a 
pseudo-spherical shape. In PP2 and SU6656-treated cells microtubule cytoskeleton 
was similar to control cells, although in presence of PP2 cells appeared elongated and 
with SU6656 cell size increased and multinucleation was induced (Figure 13A). These 
effects of SU6656 on cell morphology support the hypothesis that this compound 
blocked cell division. 
To confirm this presumption, a time-lapse video microscopy of cell cultures was 
carried out in presence of DMSO or SU6656 for 24 h. While control cells progressed 
through the cell cycle, SU6656 treated cells detached from the plate and before 
cytokinesis occurred they re-attached giving rise to enlarged multinucleated cells 
(Suppl. Videos S1 and S2). 
To test whether the effects on cell morphology were due to inhibition of SFKs 
catalytic activity, SYF cells were double-labelled with α-tubulin and DAPI. Analysis by 
fluorescence microscopy revealed that Dasatinib or PP2 did not provoke significant 
Figure 12. Analysis of morphological features of MDA-MB-231 cell cultures by phase contrast 
microscopy. (A) Induction of three different phenotypes in cells treated for 24 h with Dasatinib (100 nM), 
PP2 or SU6656 (5 μM) versus DMSO (control). Scale bar, 50 µm. (B) MDA-MB-231-shRNA-c-Src cells 
treated with 2 μg/ml Doxy for 72 h showed no cell shape modifications as compared to untreated cells. (C) 
MDA-MB-231-SrcDN cells treated with 1 μg/ml Doxy for 72 h depict no phenotypic changes. Scale bar, 100 
µm. 
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shape changes. In contrast, SU6656 induced the appearance of enlarged and 
multinucleated SYF cells (Figure 13B).  
Furthermore, MDA-MB-231 cells treated with SU6656 showed an increase in cell 
size and multinucleation similar to those provoked,  by ZM447439, inhibitor of Aurora B 
kinase (Figure 14). These results, together with the cell cycle profile and the histone H3 
phosphorylation, suggest that SU6656 inhibited cell division of MDA-MB-231 cells by 
inhibiting Aurora B kinase activity. 
To further characterize modifications in cell shape caused by Dasatinib, PP2 and 
SU6656 in MDA-MB-231 cells, we analysed β-catenin and p120-catenin distribution as 
well as actin cytoskeleton organization by confocal microscopy. We observed β-catenin 
and p120-catenin relocalization to the cytoplasmic membrane in cells treated with the 
three compounds when compared with control cells, while total expression levels of 
both proteins remained unaltered (Figure 15A and 15B). 
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Figure 14. Comparative effects of SU6656 and ZM447439 on MDA-MB-231 cell morphology. 
Immunofluorescence micrographs of cells treated with DMSO (Control), SU6656 or ZM447439 (5 µM) for 
24 h. Cells were labelled for DNA (DAPI, blue) and for microtubules (anti-α-tubulin, green). Scale bar, 10 
µm. Arrows show multinucleated cells.  
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2.6. Distinct gene expression profiling induced by Dasatinib, PP2 and 
SU6656 
Since SU6656 provoked different effects compared to Dasatinib and PP2 in cell 
cycle regulation and morphology, we engaged analyses of gene expression profiles 
induced by these compounds. All studies were carried out in triplicate and RNA was 
used to hybridize Agilent microarrays. One of SU6656 triplicate was discarded because 
it did not pass quality control standards. All treatments resulted in gene expression 
changes. Using a statistical cut-off of adjusted P value ≤0.05, we obtained 1866 
differentially expressed probes (1641 annotated sequences) after Dasatinib treatment, 
21 after SU6656 (15 annotated sequences) and 16 probes after PP2 treatment. The 
complete list of genes is provided in Suppl. Table 1. Unsupervised hierarchical 
clustering of all individual data representing all selected differentially expressed 
sequences is shown in Figure 16A. There are two clearly defined clusters on x-axis, 
one for Dasatinib treatment and the other for PP2, SU6656 and control. Into this group 
were defined two clusters PP2 and SU66565-control. Therefore, Dasatinib defined a 
strong differential gene pattern compared to control. On the contrary, SU6656 gave rise 
a gene expression profile similar to control, except for two groups of genes. PP2 shown 
a gene pattern intermediate between Dasatinib and SU6656, in most cases effects 
were similar to Dasatinib but at lower intensity. On y-axis is shown relative intensity of 
the probes and two main clusters of differentially expressed genes (up-regulated and 
down-regulated) were defined. The comparisons of each individual treatment versus 
control using plot profile representations are shown in Figure 16B. These plots show 
expression values along different samples for probes selected as differentially 
expressed in the three treatment groups. The data indicated that Dasatinib produced 
dramatic changes of gene expression that diverged from control and SU6656 samples 
and to lower degree from PP2. Although only a reduced number of genes passed the 
statistical analysis after PP2 treatment, the plots showed that there was a great 
similarity between PP2 and Dasatinib. The PP2 versus Control analysis showed two 
main clusters, PP2-Dasatinib, and SU6656-Control. Instead, in the evaluation of 
SU6656 versus Control, a set of genes defined in an individual group that differed from 
the rest of treatments. In addition, almost all genes selected in PP2 and Dasatinib 
groups did not alter their expression after SU6656 treatment. 
Furthermore, to study pathways of gene expression related to biological functions 
analysed above upon different treatments, GSEA (110) was applied using annotations 
from BioCarta, KEGG and Reactome pathway databases together with Src gene set 
previously reported (9). The analyses (Suppl. Table 2) showed that most of the 
pathways detected were down regulated in each treatment. Exceptionally, glycolysis 
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was up-regulated in Dasatinib-treated cells, while asthma and autoimmune thyroid 
disease were increased in PP2-treated cells. Dasatinib, PP2 and SU6656 shared some 
pathways, such as, pathways involved in different processes of cell cycle regulation, 
immune system and metabolism of lipids and lipoproteins. However, other pathways 
were more specific. Dasatinib and PP2 shared pathways involved in signalling by 
EGFR in cancer, by GPCR and by NGF. In addition of cell cycle regulation, metabolism 
of carbohydrates was common in PP2 and SU6656, while pathways involved in renal 
cell carcinoma, pancreatic, bladder and colorectal cancer and WNT signalling 
appeared to be specific for SU6656. Interestingly, GSEA analyses of Src gene pathway 
(Suppl. Table 3) showed a significant reduction upon SU6656 treatment (FDR=0.024), 
while PP2 and Dasatinib treatments had FDR >0.05 (0.083 and 0.193, respectively). 
 
 
  
 76 
Results 
 
 
 
 
 
 
 
 
 
 
Figure 16. Gene expression profiles regulated by Dasatinib, PP2 and SU6656. (A) Hierarchical 
clustering (heat map) of all individual data representing the differentially expressed sequences after three 
treatments at P-adjust ≤0.05. Columns correspond to samples; row corresponds to individual probe sets. 
Intensities were normalized across the rows. Normalized log intensity values of probes were centred to the 
median value of each probe set and coloured on a range of + 2 (red) and - 2 (blue). (B) Comparisons 
between effects of Dasatinib, PP2 and SU6656 treatments are shown in plot profiles. Signal intensities are 
normalized as in heat map and expression values are coloured based on the overall pattern. For each 
pattern, a loess (logical weighted polynomial regression) fit line describes the overall profile of 
corresponding group. This tendency profile is plotted up-regulated sequences (Cluster 1,green) and down-
regulated sequences (Cluster 2, orange). 
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3. INHIBITION OF MIGRATION AND INVASION CAUSED BY SFKs 
INHIBITORS, c-Src DEPLETION AND SrcDN EXPRESSION 
 
3.1. Effects in SFKs substrates involved in migration, invasiveness and 
cell motility 
Src Family Kinases, play key roles in regulating cell adhesion and migration by 
promoting changes in membrane dynamics through modulation of Rho GTPase activity 
(121), focal adhesion turnover (35) and actin cytoskeletal rearrangement (21,116). Src 
associates with focal contacts where phosphorylates Fak, p130CAS and paxillin, 
promoting focal adhesion turnover. Besides, caveolin 1 is an effector of Rho/ROCK 
signalling in the regulation of focal adhesion turnover and, its phosphorylation in 
tyrosine 14 is dependent on Src (57). Therefore, phosphorylation of these proteins was 
tested by Western blot from cells grown in presence of Dasatinib, PP2 or SU6656 for 
24 h or in presence of Doxy for 72 h to induce shRNA-c-Src or SrcDN expression. A 
decrease in phosphorylation levels of Y925-Fak, Y118-paxillin, pYp130CAS and Y14-
caveolin was observed after inhibition of the catalytic activity of SFKs and c-Src 
suppression. Additionally, c-Src depletion provoked a reduction in the 
autophosphorylation site Y397 of Fak. No modification or increased in some proteins 
including pY118-paxillin or pY14-caveolin was observed after SrcDN expression (data 
not shown). However, the inhibition of SFKs activity, as well as the expression of 
SrcDN (Figure 17A and 17C) or, in a lesser extent, c-Src suppression provoked a 
diminished phosphorylation of S473-Akt (Figure 17B). The serine/threonine kinase Akt 
is also involved in migration and invasion of cancer cells (132). 
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3.2. Inhibitors of Src family kinase activity, c-Src suppression or SrcDN 
expression reduced cell migration 
In view of the effects on phosphorylation of proteins from focal adhesion complex, 
we tested cell migration by performing a wound-healing assay. SFKs catalytic activity 
inhibition by addition of Dasatinib, PP2 or SU6656 to cultures for 20 h resulted in a 
highly significant reduction of migration ability as compared to control DMSO-treated 
cells. Dasatinib reduced migration by 75%, while PP2 and SU6656 by nearly 60% 
(Figure 18A). Suppression of c-Src, also inhibited cell migration although to a lower 
extent than SFKs selective inhibitors, 10% (Figure 18B). To confirm the low reduction 
in migration by shRNA-c-Src cells, we deeply analysed migration by random migration 
assays in subconfluent conditions. A significant reduction of mean velocity and 
distance travelled by c-Src depleted cells was observed as compared to Doxy-
untreated cells (Figure 18C). For its part, the induction of SrcDN caused similar effects 
on cell migration, with a significant reduction of 23% compared to control cells (Figure 
18D).  
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Figure 18. Inhibition of SFK activity, c-Src depletion or SrcDN expression reduced MDA-MB-231 cell 
migration. Wound-healing migration assay was performed to determine cell motility. Cell monolayers were 
wounded with a sterile 200 μl pipette tip and washed with serum-free medium. Cells were photographed at 
0 h and after 20 h incubated in complete medium. Cell motility was quantified with Image J and wound 
healing area was calculated relative to control at 0 h (100%). (A) Representative images of wound-healing 
assay from MDA-MB-231 cells treated with DMSO (control), Dasatinib (100 nM), PP2 or SU6656 (5 µM) for 
20 h. (B) MDA-MB-231-Tet-On-shRNA-c-Src cells in presence or absence of 2 µg/ml Doxy for 72 h, to 
suppress c-Src. (C) Mean velocity and accumulated distance was calculated with Image J from at least 63 
c-Src depleted cells in random migration assays. (D) Wound-healing assay after SrcDN expression with 1 
µg/ml Doxy. Graphs represent mean ± SD of three independent experiments. **p<0.01 and ***p<0.001 
(Student t-test). 
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3.3. Invasiveness alteration by SFKs inhibition, c-Src depletion or 
SrcDN expression 
Src family kinases are essential to form invadopodia, structures involved in ECM 
degradation enriched in proteases such as matrix metalloprotreases 2 and 9 (MMP-2 
and MMP-9) (13,84). An in vitro invasion assay with Matrigel-coated transwells was 
carried out to determine the effects of SFKs activity inhibition, as well as, expression of 
shRNA-c-Src and SrcDN. A significantly reduction in cell invasion was observed after 
treatment with either of the three inhibitors (Figure 19A). Furthermore, c-Src 
suppression and SrcDN induction caused a similar effect on cell invasion with a 
significant reduction of 65% and 50%, respectively (Figures 19B and 19C). Cellular 
expression of proteases by Western blot analysis revealed that neither c-Src depletion 
nor SrcDN expression modified protein levels (data not shown). Therefore, we 
determined secreted MMP levels after shRNA-c-Src and SrcDN expression by 72 h of 
Doxy treatment. Immunoblot analysis revealed a reduction in MMP-2, MMP-7 and 
MMP-9 in both cases (Figure 19D), which is consistent with reduced cellular invasion.  
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3.4. shRNA-c-Src expression induced modifications in secretome  
In order to determine additional proteins specifically controlled by c-Src involved in 
cell migration and invasion, we characterized the secretome from shRNA-c-Src cells. 
To this end, cell cultures were treated with Doxy (2 μg/ml, 72 h) for the last 24 h cells 
were grown in serum free medium and the conditioned medium was collected. These 
medium was spin down, labelled with iTRAQ and analysed by MALDI TOF/TOF. 
Protein identification and quantitation were done by using MASCOT v2.3.01 and 
Figure 19. Reduced invasion capacity of MDA-MB-231 by inhibition of SFK activity, c-Src 
suppression or SrcDN expression.  Boyden chamber assay was performed on Matrigel-coated transwell 
(8 µM membrane) by seeding 5x104 cells in serum-free medium. (A) After 24 h- incubation in presence of 
DMSO (C), Das, PP2 or SU, the lower surface of the filters were stained with DAPI and at least 4 
fields/insert were counted.(B) Invasion of c-Src depleted cells after 48 h of Doxy (2 μg/ml) treatment. (C) 
Invasiveness of cells with induced expression of SrcDN by 1 μg/ml of Doxy for 48 h. Assays were 
quantified as above and the number of invasive cells were determined after 24 h. Graphs display mean ± 
SD of at least three independent experiments made in triplicate (*p<0.05, **p<0.01 and ***p<0.001; 
Student t-test). (D) Western blots of MMP-2, 7 and 9 from secretome extracts of cells with c-Src depletion 
or SrcDN expression for 72 h are shown. Representative blots from three independent experiments are 
shown. 
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Phenyx v2.6 search engines. Twenty proteins differentially expressed were identified, 
13 down-regulated and 7 up-regulated (Table 1). Among down-regulated proteins in 
Src-suppressed cells appeared Cyr61, β-2 Microglobulin (B2M), Insulin-like growth 
factor binding protein 4 (IGFBP4), Conective tissue growth factor (CTGF), etc. The 
most underexpressed protein, approximately 3.5-fold change,  was Cyr61, an 
extracellular matrix-associated signalling protein, involved in migration, angiogenesis, 
as well as, tumourigenesis and breast cancer progression (68,123). We then 
determined cellular mRNA and protein expression levels of Cyr61 by qRT-PCR and 
Western blot, respectively. No differences in CCN1 levels (mRNA of Cyr61) between c-
Src depleted and control cells were found. Besides, Cyr61 protein levels from total 
extracts resulted unaltered. However, secreted Cyr61 was reduced in c-Src depleted 
cells compared to control cells, according to proteomic analysis (Figure 20A). Similarly, 
in SrcDN induced cells, Cyr61 mRNA and protein levels were unaltered. Furthermore, 
Cyr61 expression was reduced in total secretome (Figure 20B). In contrast, Dasatinib 
and PP2 decreased Cyr61 expression in total MDA-MB-231 cell extracts compared 
with DMSO treated cells (control). No effects on Cyr61 expression were observed after 
SU6656 treatment (Figure 20C). In addition, to test if the presence of Doxy in culture 
medium could affect directly to Cyr61, total secretome from control and Doxy-treated 
MDA-MB-231 cells was collected. Proteins were precipitated with methanol/chloroform 
and analysed by western blot; no differences were observed in Cyr61 expression 
(Figure 20D). 
 
 
 
 
 
Table 1. Summary of secreted proteins identified by MALDI TOF/TOF. Thirteen secreted proteins were 
down-regulated and seven were up-regulated in shRNA-c-Src cells after Doxy treatment (p<0.05).  
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3.5. Colocalization of Cyr61 with secretory pathway structures in MDA-
MB-231-Tet-On-shRNA-c-Src cells 
Given the fact that no modifications in mRNA and intracellular protein levels of 
Cyr61 were observed, we hypothesized that secretory pathway could be altered. 
Lechner et al. described for first time that the human Cyr61 localized to the secretory 
pathway in human osteoblasts (65), so we analysed by immunofluorescence 
microscopy cellular distribution of gp74. This membrane glycoprotein is found mainly 
in cis-Golgi network but also in tubulovesicular structures and ER foci (4). The partial 
colocalization between Cyr61 and gp74 observed in shRNA-c-Src cells (Pearson’s 
coefficient > 0.5) (12) was not modified by c-Src depletion (Figure 21A). Furthermore, 
Figure 20. Cyr61 expression in secretome and whole-cell extracts . (A) MDA-MB-231-Tet-On-shRNA-
c-Src cells were grown in presence or absence of 2 μg/ml Doxy for 72 h. mRNA was extracted to quantify 
by qRT-PCR the relative expression of CCN1 (Cyr61) using GAPDH as endogenous control. Lysates from 
whole-cell extracts or protein precipitated from secretome were used to determine Cyr61 protein levels by 
Western blot. (B) MDA-MB-231-Tet-On-SrcDN cells were treated or not with 1 μg/ml Doxy for 72 h, mRNA 
and Cyr61 protein levels were determined as above. Graphs depict mean ± SD of three distinct 
experiments. (C) MDA-MB-231 cells treated with DMSO (C), PP2, SU6656 (5 μM) or Das (100 nM) for 24 
h, mRNA was determine as above and Cyr61 protein levels of total cell lysates were determined by 
Western blot. (D) Doxy at 2 µg/ml for 72 h had no effects on Cyr61 levels in secretome of MDA-MB-231 
cells. Representative blots from at least 3 independent experiments are shown. 
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we studied colocalization with CD63, a tetraspanin present in late endosomes, 
lysosomes and exosomes (98). We found that suppression of c-Src did not affect the 
partial colocalization between Cyr61 and CD63 (Pearson’s coefficient > 0.5) (Figure 
21B). Altogether, these results suggest no alteration in Cyr61 cellular distribution upon 
c-Src suppression. 
 
 
 
 
 
 
 
 
 
Figure 21. Confocal immunofluorescence localization of Cyr61 and gp74 or CD63. (A) Partial 
colocalization of Cyr61 (green) and the cis-Golgi marker, gp74 (red) in MDA-MB-231 unaltered by 
suppression of c-Src by 2 μg/ml of Doxy treatment for 72 h. (B) Immunofluorescence of Cyr61 (green) and 
the endosomal and exosomal marker, CD63 (red) in MDA-MB-231 cells with or without c-Src depletion for 
72 h. Scale bar, 10 μm. Random fields are shown. 
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3.6. Cyr61 is associated with the exosomal fraction 
Based on the relation of Cyr61 with the endosomal compartment, as a partial 
colocalization between Cyr61 and CD63 was observed, and since is an extracellular 
protein, we hypothesized that Cyr61 could be secreted in exosomes. To test this 
hypothesis, a differential centrifugation of secretome from shRNA-c-Src cells treated or 
untreated with 2 μg/ml Doxy for 72 h was carried out to obtain exosome-enriched 
fraction. After the last centrifugation at 100,000 xg 70 min, microvesicle pellet 
corresponding to exosomes (118) was resuspended in PBS-5mM EDTA. Supernatant 
proteins were concentrated by methanol/chloroform precipitation. Western blot analysis 
shown that Cyr61 was mainly found in fraction described by Thery et al. as exosome 
fraction (pellet P5) and a minor part was free in medium (supernatant S3). Furthermore, 
the tetraspanin CD63, described as exosome marker, was mostly detected in pellet P5. 
The quantification of three independent experiments by densitometry revealed a 
consistent reduction of Cyr61 in exosomes (Figure 22A). To confirm this finding, we 
transiently transfected esiRNA-Rab27a or scramble siRNA (control) in MDA-MB-231. 
The small GTPase Rab27a plays an essential role in exosome secretion (93). We 
observed a significant knockdown of Rab27a in the cells, together with a significant 
decreased of Cyr61 and CD63 in secretome (Figures 22B and 22C). Altogether, these 
findings suggest that Cyr61 is located in exosomes.  
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Figure 22. Localization of Cyr61 in exosomes. (A) Differential centrifugation was used to isolate 
exosomal fraction (P5) from secretome of control (Doxy -) or c-Src depleted (Doxy +), Supernatants 3, 4 
and 5 (S3, S4 and S5) and pellet 5 (P5) were blotted with anti-Cyr61 and anti-CD63. (B and C) MDA-MB-
231 cells transiently transfected with scramble siRNA or esiRNA-Rab27a for 96 h. (B) Analysis of 
secretome by Western Blot for Cyr61 and CD63. (C) Anti-Cyr61, anti-CD63, anti-Rab27a and β-actin, as 
loading control, were used to determine their expression by Western blot in total cell extracts. Graphs 
represent mean ± SD from densitometric analysis of the indicated proteins for three independent 
experiments. Results are expressed in arbitrary units (for P5 and for secretome) or as target/β-Actin ratio 
(for total cell extract). Student t-test (*p<0.05, **p<0.01 and ***p<0.001). Representative blots from 3 
independent experiments are shown. 
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3.7. Decrease in transendothelial migration caused by c-Src depletion 
Lin et al. described that Cyr61 contributed to transendothelial migration and 
intravasation in  AGS human gastric carcinoma cells (68). Then, we studied whether 
Cyr61 reduction in secretome provoked by c-Src suppression was involved in 
extravasation event during metastatic cascade by performing a transendothelial 
migration assay in vitro. Control or 48 h Doxy-treated MDA-MB-231-Tet-On-shRNA-c-
Src cells were seeded on top of HUVEC monolayer grown over gelatin-coated 
transwells. In parallel, HUVEC spontaneous migration was tested by seeding the 
endothelial cells alone over gelatin-coated transwells. c-Src suppression caused a 
significantly reduction in transendothelial migration after 22 h (Figure 23); which is 
consistent with the reduction of gelatinases, matrix metalloproteases 2 and 9, observed 
in total secretome (Figure 19D). 
 
 
 
 
 
 
 
 
3.8. Silencing of Cyr61 reduced invasion and transendothelial migration 
To determine if Cyr61 mediated the effects on invasiveness and transendothelial 
migration, MDA-MB-231 cells were transiently transfected with Cyr61-siRNA or 
scramble-siRNA (Ctrl, Figure 24A), then invasion assay in Matrigel-coated transwells 
and transendothelial migration assay were performed. A decrease in invasion and 
transendothelial migration abilities were observed in Cyr61 suppressed cells compared 
to control ones (Figures 24B and 24C). 
 
Figure 23. Reduced transendothelial migration of c-Src depleted cells. Transendothelial migration 
assay was performed in MDA-MB-231-Tet-On-shRNA-c-Src cells after 48 h-treatment with 2 μg/ml Doxy. 
5x104 cells were seeded onto HUVEC monolayer and transmigrated cells were detached and counted in a 
haemocytometer at 22 h. Transmigrated cells were expressed as percentage respect to control cells 
(100%). The average ± SD of three independent experiments made in triplicate are shown. *p<0.05 
(Student t-test). 
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4. c-Src INVOLVEMENT IN ANCHORAGE-INDEPENDENT GROWTH AND 
MAMMOSPHERE FORMATION EFFICIENCY 
 
The ability of cancer cells to proliferate in the absence of adhesion to extracellular 
matrix (ECM) proteins is a hallmark of transformed cells and reflects their metastatic 
potential, as allows tumour cells to expand, invade adjacent tissues and disseminate 
through the circulation to distant organs. We tested if c-Src played a role in anchorage-
independent growth by performing a colony formation assay. To this end, MDA-MB-
231-Tet-On-shRNA-c-Src cells were seeded in 0.3% agar in complete medium over a 
0.5% agar layer, both of which in the presence or absence of Doxy. c-Src suppression 
significantly decreased the number of colonies detected after 20 days of growth (Figure 
25A). 
The ability of sphere formation is a property of cells with stemness features. To 
determine whether c-Src depletion modified this ability in MDA-MB-231 cells, 
mammosphere formation assays were performed. Sphere forming efficiency was 
significantly reduced by shRNA-c-Src induction after 20 days, compared to control cells 
(Figure 25B). In order to discard that spheres were cell aggregates instead of 
mammospheres formed from single cells, assays were also carried out in 96-well plate 
at very low cell density, obtaining comparable results (data not shown). Besides, 
according to Al-Hajj et al. CD44+ CD24- / Lineage- defined a subpopulation of cells with 
Figure 24. Silencing of Cyr61 reduces invasion and transendothelial migration. (A) Cell lysates from 
MDA-MB-231 cells transiently transfected with either scramble-siRNA (Ctrl) or siRNA-Cyr61 for 72 h were 
analysed by Western blot with anti-Cyr61 and anti-α-tubulin, as loading control. (B) Invasion assays were 
carried out with siRNA-Cyr61 and siRNA-control cells after 48 h transfection. The number of cells per insert 
was determined after DAPI stained. (C) Transendothelial migration assay was performed after 48 h siRNA-
Cyr61 and siRNA-control transfection. Transfected cells were seeded onto HUVEC monolayer. At 22h 
transmigrated cells were detached and counted in a haemocytometer. Data are presented as percentage 
of siRNA-Cyr61 transmigrated cells compared to siRNA-control (100%). Graphs depict the average ± SD of 
three independent experiments performed in triplicate are shown. Student t-test (*p<0.05 and **p<0.01). 
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the highest tumourigenic potential, that could identify breast cancer stem cells (3). 
Then we determined the expression of these surface markers by flow cytometry. A 
significantly decrease in the percentage of CD24+ cells was observed in samples 
obtained from mammospheres to those obtained from adherent cultures (Figure 25C), 
indicating that growth condition in a mammosphere defined medium could enrich the 
fraction of cells with stem-like properties. Doxy addition to mammosphere cultures 
slightly increased CD24+ fraction, suggesting a partial involvement of c-Src in the 
maintenance of stem-like population. As regard CD44 expression, almost all cells, both 
from adherent and mammosphere cultures, were highly positive for this marker. In 
addition, c-Src suppression did not induce alterations in its expression pattern (Figure 
25C, dot plot).  
To deeply characterize stem cell population, we analysed by Western blot the 
expression of pluripotency markers Oct3/4, Nanog and Sox2 in lysates from 
mammospheres. The diminished expression observed in c-Src suppressed cells 
compare to control ones (Figure 25D) could be in agreement with the reduced 
mammosphere forming ability observed in Doxy-treated samples (Figure 25B). 
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Figure 25. c-Src suppression affects colony formation in soft agar and mammospheres. (A) Average 
± SD of number of colonies in soft agar with or without c-Src expression are shown. Colonies were counted 
after crystal violet stain in contrast-phase microscope. (B) Sphere formation efficiency (SFE) was 
calculated as the percentage of number of spheres ≥ 50 μm relative to number of seeded cells after 20 
days growth in presence or absence of 2 µg/ml Doxy. Student t-test (***p<0.001). (C) Representative plots 
of CD24/CD44 labelled cells from adherent cultures and from dissociated mammospheres with or without 
c-Src suppression. Graph depicts mean ± SD of CD24+ cells from adherent cultures or from dissociated 
mammospheres of three independent experiments (*p<0.05; Student t-test). (D) Analysis of c-Src, Nanog, 
Oct3-4 and Sox2 by Western blot from lysates of mammospheres treated or untreated with Doxy (as 
above). Representative blots from at least 3 independent experiments are shown. 
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Src family kinases are involved in tumour development and metastasis of cancer 
cells, exerting their effects on cell adhesion, migration, invasion, proliferation, 
differentiation and survival (37,49,106,133). Since metastasis is the main cause of 
cancer mortality (18) and SFKs are involved in breast cancer (36), we used a highly 
metastatic breast cancer cell line, MDA-MB-231, to analyse SFKs functionality. To 
address this aim we employed three approaches: inhibition of SFKs catalytic activity by 
Dasatinib, PP2 and SU6656, suppression of c-Src and expression of SrcDN. We 
generated conditional expression of shRNA-c-Src and SrcDN because we previously 
observed that constitutive suppression of c-Src was deleterious to MCF7 cells. Besides, 
conditional expression of SrcDN in MCF7 reduced cell proliferation (41). 
 
1. INVOLVEMENT OF SFKs ACTIVITY IN MDA-MB-231 CELL 
PROLIFERATION 
 
Given that SFKs are involved in cell proliferation, we determined cell growth by 
trypan blue exclussion and MTT assays. The inhibition of Src catalytic activity by three 
different selective inhibitors, Dasatinib, PP2 and SU6656, caused a reduction of 
pY418-Src and diminished proliferation of the triple-negative/basal-like breast cancer 
cell line, MDA-MB-231. However, no significant effects were observed on cell 
proliferation after c-Src suppression or SrcDN expression. This is in agreement with 
Brunton and collaborators work, where is shown that the expression of SrcDN or 
kinase defective Src (Src251) in KM12C colon epithelial cancer cell line did not alter in 
vitro or in vivo cell growth (14). However, in contrast to our findings, Rucci et al. 
showed a decreased in proliferation after constitutive expression of SrcDN in MDA-MB-
231 cells (102). 
Dasatinib and PP2 increased G1 and reduced S and G2/M cell cycle phases, 
together with an increase in p27Kip1 and a reduction in c-Myc expressions. No 
modifications in cell cycle profiles were observed after Dasatinib or PP2 treatment on 
SYF fibroblasts suggesting that the effects on cell cycle are mediated by SFKs. The 
inhibition of G1 to S phase cell cycle transition was also detected after Dasatinib or 
PP2 treatment of different cell types, including MDA-MB-231, MCF7, T47D, head and 
neck squamous cell carcinoma, as well as, non-small cell lung cancer cell lines (56,97). 
Furthermore, treatment with each of the three inhibitors did not cause apoptosis, as no 
significant proportion of cells in subG1 phase was observed, as well as, no PARP 
degradation (data not shown), demonstrating that these compounds do not provoke 
apoptosis at the chosen concentrations. However, Dasatinib stimulated apoptosis in 
MDA-MB-468, by activating caspases-8 and -9, as well as, in bone sarcoma cell lines 
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(90,107). These observations are in contrast with our results, probably because of the 
dose used. Altogether these findings indicate that SFKs activity is involved in cell 
proliferation, by regulating G1-S transition through p27Kip1 and c-Myc in MDA-MB-231 
cell line. They are in accordance with previous results obtained in MCF7 cell line where 
it has been shown that SFKs are involved in G1-S progression, associated with an 
increase in p27Kip1 (41). 
In contrast, SU6656 provoked a progressive decrease in G1 and S phases, as well 
as, an increase in G2/M and >4N phases. The proportion of cells with DNA content 
higher than 4N increased with the time of treatment, reducing the amount of cells in the 
remaining phases, thus there is an accumulation of polyploid cells caused by SU6656. 
Besides, MTT metabolic assay can be used as a viability assay, since the 
transformation of tetrazolium salt into formazan only takes place in living cells with 
functional mitochondria. The results showed a discrepancy between trypan blue 
proliferation assay and MTT metabolic assay. The trypan blue assay revealed a 
proliferation rate of 30%, whereas metabolic activity determined by MTT assay was 
around 55%. It may due to cells progress through the cell cycle, duplicate organelles, 
including mitochondria, but they fail in cell division. Furthermore, since the effect of this 
inhibitor was similar in both MDA-MB-231 and SYF cells, we conclude that is not due to 
the inhibition of SFKs activity but to an additional kinase involved in mitosis. The main 
mitotic protein kinases described are Cyclin-dependent kinase 1 (Cdk1), Pole-like 
kinase 1 (Plk1), NIMA-related kinase 2 (Nek2) and Aurora kinases (92). The Aurora 
family of serine/threonine protein kinases is involved in centrosome separation and 
maturation, spindle assembly and stability, chromosome condensation, segregation 
and cytokinesis. In mammalian cells there are three members, Aurora-A, -B and –C, 
that are overexpressed in many types of cancers (40). Among the three Aurora kinases, 
Aurora-B and –C are inhibited in vitro by SU6656 (6). Although both Aurora kinases 
have similar functions, Aurora C kinase protein appears in germ cell in the testis (124), 
then Aurora B could be responsible for the effects caused by SU6656 in our cellular 
model. The use of other Aurora B kinase inhibitor, ZM447439 (31), gave rise to a cell 
cycle profile similar to that observed after SU6656 treatment, characterized by 
diminished G1 and S phases, as well as, increased G2/M and >4N phases. 
Furthermore, we observed that SU6656 and ZM447439 inhibited phosphorylation of 
the canonical substrate of Aurora B kinase, S10 of histone H3 (40,117). These findings 
were confirmed by immunofluorescence microscopy of mitotic MDA-MB-231 cells in 
presence of SU6656 or ZM447439, where a decreased staining of pS10-H3 was 
observed. In vitro kinase assay revealed a reduction of S10-H3 phosphorylation in 
presence of SU6656. Polyploidization and multinucleation induced by SU6656 were 
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also observed in SUM159 and MCF7 breast cancer cell lines (data not shown), and in 
leukaemic UT-7/TPO, K562 and HEL cell lines (63). The induction of these alterations 
both in p53 wt (MCF7) and in p53 mutant cell lines (MDA-MB-231, SUM159) indicate 
that the mechanism involved is p53 independent. Altogether, these findings suggest 
that SU6656 alters cytokinesis, as well as, previous mitotic events by inhibiting Aurora 
B kinase, an effect that is observed in other cell types. 
GSEA analysis of gene set expression confirmed the results obtained, because the 
three inhibitors down-regulated pathways related to cell cycle, including DNA 
replication (KEGG), mitotic cell cycle, G1-S transition and DNA repair (Reactome). 
Interestingly, GSEA analysis also showed that SU6656 significantly reduced Src gene 
set expression. 
Since c-Src suppression did not inhibit cell proliferation, we can suggest that c-Src 
is not essential in the process. Similarly, constitutive suppression of c-Src in bone-
derived metastatic MDA-MB-231, BoM-1833 cells, did not alter cell proliferation (138). 
Interestingly, in the non-metastatic MCF7 cells, constitutive suppression of c-Src 
greatly reduces their proliferation (41). The immunoprecipitation of several SFKs 
members and the subsequent use of the pY418-Src antibody revealed that Src and 
Fyn were the main activated SFKs members in MDA-MB-231 (data not shown). Fyn 
has been associated with cell growth, particularly the expression of kinase dead Fyn 
reduced tumour weights in a mouse squamous cancer model (104). Lu et al. shown 
that the inhibition of Fyn and Src by Dasatinib or the knockdown by siRNA blocked 
EGFR-dependenty motility and tumour growth in glioblastoma (72). So, it is not strange 
that the catalytic activity of other SFKs members, such as Fyn, could be responsible for 
cell proliferation in MDA-MB-231. 
Cell proliferation was not only affected in two-dimensional culture conditions, since 
we observed that the inhibition of Src family kinase activity decreased cell growth in 
three-dimensional Matrigel conditions. Particularly, Dasatinib and PP2 reduced the size 
of colonies, whereas SU6656 prevented their formation. Similarly to the results 
obtained in two-dimensional cultures, SU6656 inhibited cell division by altering 
cytokinesis. Addition of PP2 or SU6656 after 21 days of colony formation did not 
provoke any effect, whereas Dasatinib reduced colony size. These data suggest that 
the Src family kinase activity participates in colony development in three-dimensional 
cultures of MDA-MB-231 cells, and the effect of Dasatinib on colonies already formed 
is a side-effect caused by the inhibition of additional targets.  
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2. MORPHOLOGICAL ALTERATIONS AFTER SFKs ACTIVITY INHIBITION 
  
Alterations of cell migration and invasion require dynamic reorganization of the 
actin cytoskeleton, which in turn can lead to a change in cell morphology. Inhibition of 
SFKs catalytic activity by Dasatinib, PP2 and SU6656 resulted in an altered phenotype. 
In contrast, c-Src suppression or SrcDN expression did not provoke significant 
morphological changes. Surprisingly, each compound gave rise to a different 
phenotype. SU6656-treated cells became enlarged and more flattened. As mentioned 
previously, SU6656 disrupted cytokinesis in MDA-MB-231 cells, as well as, in SYF 
fibroblasts, giving rise at similar shape in both cases. Besides, time-lapse imaging from 
SU6656-treated MDA-MB-231 cells showed that they detached from the plate to divide 
then reattached again without division, giving rise to enlarged cells. As SYF cells lack 
Src, Yes and Fyn, we can conclude that morphological alterations provoked by SU6656 
occur in a Src kinase activity-independent manner.  
Dasatinib caused rounded cells with a collapsed cytoskeleton, similar to the 
phenotype observed by Pichot and colleagues after treatment of breast cancer cells 
(97). Immunofluorescence micrographs of Dasatinib-treated cells showed relocalization 
of β-catenin and p120-catenin, as well as collapse of the actin cytoskeleton. 
Interestingly, expression of the thermo-sensitive LA29 v-Src in chicken fibroblasts by 
switching temperature, results in loss of organized actin stress fibers and focal-
adhesion structures, giving rise to rounded morphology and reduced adhesiveness (38). 
PP2 gave rise to an elongated cell shape spindle-like phenotype caused by a lower 
effect over actin cytoskeleton. Besides, Dasatinib or PP2 did not significantly alter SYF 
morphology. Thus, altogether suggest that overactivation or inhibition of SFKs catalytic 
activity alters cellular morphology by disorganization of cytoskeleton as well as focal 
adhesions. 
 
3. SFKs IN FIRST STEPS OF METASTASIS: MIGRATION AND INVASION 
 
SFKs are involved in focal adhesion turnover and cytoskeleton reorganization that 
finally control cell motility and, in turn, cell migration and invasion. Cellular stimulation 
facilitates c-Src interaction with actin fibers and its movement from perinuclear region 
to plasma membrane, where participates in the focal adhesion complexes (35,105). 
Integrins link extracellular matrix to cytoskeleton through a complex of several proteins 
including Fak, whose autophosphorylation creates a binding site for SH2 domain of Src. 
Fak-Src complex phosphorylates other proteins such as p130CAS, paxillin or caveolin 
1 promoting focal adhesion turnover and the movement of the cell (16,127). Inhibition 
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of SFKs catalytic activity by Dasatinib, PP2 and SU6656 resulted in reduction of 
phosphorylation of these Src-Fak substrates, and consequently a decrease in cell 
migration and invasion. Accordingly, Dasatinib, PP2 or SU6656 did not alter migration 
of SYF fibroblasts (data not shown). c-Src depletion or SrcDN also reduced cell 
migration. Similarly, in MCF7 cells constitutive suppression of c-Src or conditional 
expression of SrcDN inhibits cell migration (41). Similar findings were obtained after 
SrcDN constitutive expression in MDA-MB-231 cells (102). Altogether, these data 
suggest an essential role of the catalytic activity of SFKs, as well as, an important role 
of the prototypic member of SFKs, c-Src, in cell migration. Surprisingly, we did not 
observe a reduction in Y118-paxillin or Y14-caveolin 1 phosphorylation after SrcDN 
expression in MDA-MB-231, which is in contrast with observed in MCF7 cells (41) and 
in KM12C colon epithelial cancer cells after SrcDN expression. Furthermore, KM12C 
has an altered migratory phenotype after SrcDN expression, but phosphotyrosine 
content of Fak is increased, as well as, in SYF cells. Besides, it is shown that the SH2 
domain of Src is essential for both recruitment of Src-Fak to focal adhesions and 
increased phosphorylation of Fak (14). Overall, these data might indicate that SrcDN in 
MDA-MB-231 recruits Fak to cell membrane where is constitutively associated with 
adhesion complexes avoiding dephosphorylation of focal adhesions proteins. 
Nevertheless, we observe decreased activation of Akt, measured by S473 
phosphorylation, a protein involved in migration and invasion in several cancer cell 
types (19,59,81,95,132). SFKs inhibition, SrcDN expression and to less extent c-Src 
suppression reduced S473-Akt phosphorylation in MDA-MB-231. Knockdown of  Abl 
interactor 1 (Abi1) in MDA-MB-231 cells decreases cell proliferation, migration and 
invasion (112,126). Wang et al. also found an alteration in lamellipodia formation, as 
well as, an alteration of PI3K/Akt pathway (126). Sun and colleagues also observed an 
inhibited Src-Id1-MMP-9 pathway and altered invadopodia formation, as well as, ECM 
degradation. Besides, PP2 treatment inhibited Src activation accompanied with a 
reduced Id1 expression and MMP-9 production (112).  
Invasion assay revealed a similar reduction after SFKs enzymatic inhibition by 
Dasatinib, PP2 and SU6656. Also, c-Src suppression and SrcDN expression inhibited 
cell invasion. Besides, SrcDN expression or c-Src depletion reduced MMP-2, MMP-7 
and MMP-9 in the secretome. Similarly, the SFKs catalytic inhibitor PH006 also inhibits 
MMP-2/9 and MDA-MB-231 cell invasion (75) and, in A549 and H1299 lung cancer cell 
lines, SU6656 inhibits expression of MMP-2/9 required for cell invasion (74). Also, in 
the head and neck human cancer cell lines 1483 and PCI-37a, SFKs catalytic activity is 
required for cell invasion (135). In MDA-MB-231 cells constitutive expression of SrcDN 
diminished cell invasion (102). Altogether these findings suggest that SFKs catalytic 
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activity is essential for invasiveness of MDA-MB-231. Furthermore, c-Src plays a key 
role in this process, since its suppression reduces it in a similar extent.  
Several studies support our results, since Dasatinib reduces migration and invasion 
in TNBC cell lines MDA-MB-231 and MDA-MB-468 (122), and in SaOS-2 and U-2 OS 
human sarcoma cell lines, together with an inhibition of p130CAS (107). This 
compound also suppresses migration and invasion of human melanoma cell lines, 
A2058 and 1205-Lu (15). In the lung cancer cell line A549, PP2 treatment diminishes 
migration and invasion by approximately 50% (82). 
In conclusion, MDA-MB-231 migration and invasion abilities are mediated by SFKs 
catalytic and scaffold functions through several pathways, including PI3K/Akt. 
 
4. c-Src MODULATES SECRETOME OF MDA-MB-231 CELLS 
 
The characterization of secretome in c-Src suppressed MDA-MB-231 cells resulted 
in 20 proteins differentially expressed; among them, 13 were down-regulated whereas 
7 appeared up-regulated. Down-regulated genes include Cysteine-rich protein 61 
(Cyr61), β-2-Microglobulin (B2M), Insulin-like growth factor-binding protein 4 (IGFBP4), 
and Connective tissue growth factor (CTGF). Among secreted up-regulated genes we 
found Manganese superoxide dismutase (SOD2), Transketolase (TKT), as well as, 
several histones, Histone H2B type 2F (HIST2H2BF), Histone H4 (HIST1H4A), Histone 
H3.2 (HIST2H3A), etc. 
In secretome of c-Src depleted cells, down-regulation of Cyr61 by around 3.5 fold 
respect to control cells was confirmed by Western blot analysis. The treatment with the 
three selective SFKs inhibitors showed a diminished mRNA only in Dasatinib-treated 
cells, which is in agreement with gene expression analysis (Suppl. Table 1), as well as 
reduced protein levels of Cyr61, indicating a regulation of Cyr61 expression by this 
compound. Lai and colleagues found that cotransfection of the transcription factor 
TEAD with the coactivator TAZ in breast cancer cells significantly enhanced activation 
of Cyr61 promoter. Besides, TEAD4 has been described as the most important 
member of its family in TAZ-induced tumourigenesis (62). Thus, Dasatinib might 
regulate Cyr61 expression at transcriptional level through regulation of TEAD4, since 
gene expression analysis revealed down-regulation of TEAD4 in Dasatinib-treated cells, 
whereas it remained unaltered after PP2 or SU6656 treatment (Suppl. Table 1). PP2 
caused a slight reduction of Cyr61 at protein level but not at mRNA level, which 
suggest post-transcriptional regulation. Since regulation of Cyr61 cellular expression by 
the SFKs catalytic inhibitors, Dasatinib, PP2 or SU6656 is different, and neither 
shRNA-c-Src nor SrcDN altered Cyr61 cellular expression, we can conclude that 
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control of Cyr61 cellular expression is independent of catalytic activity, c-Src or scaffold 
function of SFKs.  
Confocal immunofluorescence microscopy analysis of Cyr61 and glycoprotein gp74, 
a cis Golgi marker (4), as well as Cyr61 and CD63, a marker of late endosomes, 
lysosomes and exosomes (34,80), show that Cyr61 is localized in secretory pathway. 
We observed that c-Src depletion did not change Cyr61 distribution, suggesting that c-
Src may not regulate this part of the secretory pathway of Cyr61. However, c-Src 
depletion or SrcDN expression reduced Cyr61 in secretome, indicating that c-Src 
modulates the levels of secreted Cyr61.  
Cyr61 involvement in metastasis is well documented. Lin and colleagues showed 
that the monoclonal antibody anti-Cyr61, 093G9, which inhibits Cyr61 functionality, 
reduced proliferation of MDA-MB-231, as well as, diminished lymph node metastasis in 
vivo (69). Besides, Cyr61 participates in metastasis of hepatocellular carcinoma and 
prostate cancer cells (113,134). This CCN family member mediates cell proliferation, 
migration, adhesion, angiogenesis and differentiation (25). Cyr61 is highly expressed in 
invasive and tumourigenic breast cancer cell lines, MDA-MB-231, MDA-MB-436, MDA-
MB-157, T47D and BT474; whereas its expression is reduced in less tumourigenic 
ones, MCF7, BT-20 and ZR-57-1 (130). The ectopic expression of Cyr61 in MCF7 gave 
rise to oestrogen-independent growth, both in anchorage-independent and –dependent 
conditions. In mouse models, overexpression of Cyr61 in MCF7 cells, increases tumour 
growth, as well as, density of blood vessel in the tumours (123,130). Cyr61 is 
associated with the extracellular matrix and we found a small portion of Cyr61 as 
soluble-secreted protein. However, the majority of Cyr61 is released into exosomal 
microvesicles in breast carcinoma MDA-MB-231 cell line. Indeed, siRNA suppression 
of Rab27a in MDA-MB-231 cells significantly inhibited CD63 and Cyr61 in the 
secretome. In this context, Jenjaroenpun and co-workers determined exosomal mRNA 
and miRNA profiles by RNA sequencing, they found mRNA of Cyr61 in exosomes of 
MDA-MB-231 and MDA-MB-436 (53). 
Exosomes are vesicles of endocytic origin that transfer information, such as, mRNA, 
miRNA and proteins to recipient cells. These microvesicles can act locally, on cancer 
cells and stroma to promote tumour growth, or distantly to prepare niche for cancer cell 
implantation and growth. Active MT1-matrix metalloprotease is secreted in exosomes 
to degrade type 1-collagen fibers. Invasive breast cancer cells released exosomes 
containing HSP90α, a chaperone that activates extracellular proteases, including MMP-
2 and plasmin. Amphiregulin, EGF and TGF-α, HER ligands, are components of cancer 
exosomes. Furthermore, they induce angiogenesis and proteomic analysis revealed 
pro-angiogenic factors in their composition (46). Regarding to the modification of 
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metastatic niche, Peinado and colleagues showed that melanoma-derived exosomes 
promote metastatic niche formation through modification of bone marrow-derived cells. 
Besides, exosomal microvesicles from patients with metastatic melanoma have higher 
protein concentration. Exosomes derived from a metastatic melanoma cell line were 
injected in mice and later localized in lung, bone marrow, liver and spleen, common 
sites of melanoma metastasis. Furthermore, exosomes altered vascular permeability in 
the lung, that is an event in the formation of premetastatic niche (94). We observed a 
diminished invasive capacity in Matrigel after c-Src suppression, as well as, after 
transient silencing of Cyr61. Furthermore, c-Src depletion or knockdown of Cyr61 
reduced transendothelial migration, which suggest that Cyr61 mediates, at least in part, 
the role of c-Src in invasion and extravasation. Moreover, c-Src also controls breast 
cancer cell dissemination by degrading the extracellular matrix, contributing to breast 
tumour cells extravasation.  
Although the expression of secreted Cyr61 is the one most affected by c-Src 
suppression, we cannot exclude the contribution of other proteins, including IGFBP-4 
or CTGF, in the regulation of MDA-MB-231 metastatic process. 
IGFBPs modulate, activating or inhibiting, the biological activity of IGF, specifically 
IGFBP4 inhibits activity of Insulin-like growth factor 1 (IGF1). The cleavage of IGFBP4 
by Pregnancy-associated plasma protein-A (PAPP-A) protease releases biologically 
active IGF (17,64). In 4T1.2 mouse mammary adenocarcinoma cells injected in an 
orthotopic model of breast cancer a protease-resistant IGFBP4 inhibits 4T1.2 tumour 
growth. Furthermore, authors suggest that it could increase tumour growth acting as a 
reservoir of IGF1. Nonetheless, wild-type IGFBP4 does not promote tumour growth in 
breast (103) whereas in other types of cancer, such as, in non-orthotopic murine 
models of colon and prostate cancers, IGFBP4 inhibits tumour growth (32,33). Our in 
vitro studies did not indicate an effect on cell growth, since the decrease of IGFBP4 
secreted after c-Src depletion does not affect proliferation rate. Further studies are 
required to deeply characterize its contribution to tumourigenesis and/or metastasis in 
MDA-MB-231 cell line. 
Xie and colleagues suggested a role for CTGF, WISP-1, as well as Cyr61, all 
members of the CCN family, in the progression of breast cancer. Particularly, they 
found that CTGF was related to stage, tumour size, lymph node metastasis and age. 
They observed that the 100% of primary breast cancers analysed with stage III or IV 
overexpressed CTGF. Furthermore, a significant correlation among CTGF, WISP-1 
and Cyr61 expression was found in the primary breast cancer studied (131). MDA-MB-
231 express high levels of CTGF whilst, MCF7, T47D or BT-474 express barely 
detectable levels. They indicate that CTGF provokes cytoskeleton rearrangement, 
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which affects migratory ability, through binding to integrin αvβ3. Besides they show that 
the prometastatic S100A4 gene is regulated by the CTGF-integrin αvβ3-Erk1/2 
pathway and contributes to metastatic ability of MDA-MB-231 cells in a lung metastatic 
mouse model (24). Given the role of CTGF in the migration ability of breast cancer cells, 
we cannot exclude that its reduced levels in secretome of c-Src suppressed cells 
contribute to diminish the motility of MDA-MB-231 cells. 
 
5. SFKs REGULATE ANCHORAGE-INDEPENDENT GROWTH AND SELF-
RENEWAL ABILITY  
 
Anchorage-independent colony formation is a measure of the capacity of cancer 
cells to escape from anoikis, and therefore to survive in absence of substrate. This 
characteristic is important for metastatic cells that must acquire the ability to survive in 
circulatory or lymphatic systems to colonize the target organs. We observed a 
reduction in the capacity of the MDA-MB-231 cells to form colonies in soft agar after c-
Src suppression, indicating that c-Src affects survival in anchorage-independent growth 
conditions. SFKs catalytic activity and tropomyosin receptor kinase C (TrkC) have been 
implicated in the survival of the highly metastatic 4T1 mouse mammary cancer cells by 
using SU6656 in the colony formation assay (55). It also has been reported the 
involvement of c-Src enzymatic activity in anchorage-independent growth of MDA-MB-
468, MCF7 and ZR-75-1 human breast cancer cell lines, as inhibitor PP1 significantly 
reduced the ability of these cell lines to form colonies in soft agar. Furthermore, the 
stable transfection of catalytically inactive c-Src into MDA-MB-468 and MCF7 reduced 
colony formation ability (50). Furthermore, Zheng et al. observed that siRNA-c-Src in 
MDA-MB-231, MDA-MB-435S, MDA-MB-436 and SKBR3 breast cancer cell lines 
diminishes colony formation in soft agar, as well as, apoptosis. Suppression of Fyn or 
Yes in MDA-MB-231 and MDA-MB-435S has no effect on anchorage-independent 
growth (139). Therefore, altogether indicates that c-Src and/or the tyrosine kinase 
activity of SFKs are needed for breast cancer cell growth in anchorage-independent 
conditions. 
Among the population of breast cancer cells that are able to survive in vascular 
system to reach distant organ, it is believed that only a small subpopulation have the 
ability to form new tumours. These “tumour-initiating cells” are often termed cancer 
stem cells (CSCs). In acute myelogenous leukaemia, a subpopulation of leukemic cells 
with markers similar to normal hematopoietic stem cells was progressively enriched in 
clonogenic assays in non-obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice. In this sense, Al-Hajj and colleagues described a subpopulation of 
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breast cancer cells, defined as CD44+ CD24-/low Lineage-, with the ability to form 
tumours more efficiently than other subpopulations with different phenotypes. This 
subpopulation seems to have properties of cancer stem cells (3). One of these 
properties is the self-renewal which allows the maintenance of stem cell population. 
Cancer cells have been demonstrated to possess this ability by serial tumour 
transplantation and sphere-formation assays (54,115). We observed that c-Src 
suppression significantly reduced the sphere forming efficiency of MDA-MB-231 cells, 
affecting the self-renewal of breast cancer stem cells. Furthermore, cells from 
mammospheres exhibited a significantly decrease of CD24+ fraction cells compared to 
adherent cells, confirming that the spheroids are enriched in breast cancer stem or 
progenitor cells. Conversely, mammospheres from c-Src depleted cells showed a slight 
increase of CD24+ cell percentage, although it was no significant. These data suggest 
that c-Src is essential to maintain the tumourigenic subpopulation in breast cancer cells. 
It has been demonstrated that the transcription factors, Oct3/4, Nanog and Sox2 
regulate and maintain the self-renewal and pluripotency of embryonic stem cells (7). 
They are involved in the development and malignant progression of various types of 
tumours. Ling et al. shown the expression of these pluripotency-associated 
transcription factors in three human breast cancer cell lines, MDA-MB-231 cells 
expressed high levels of Oct3/4 and low levels of Nanog and Sox2 compared to MCF7 
and T47D cell lines (70). The knockdown of Sox2 in MCF7 decreased cell proliferation 
and tumour growth (26). In a study of 226 breast tumours biopsies, Rodriguez-Pinilla 
and collaborators found that Sox2 expression was higher in basal-like as compared to 
luminal or HER2+ tumours (101). Down-regulation of Nanog inhibits breast, prostate 
and colon tumour development and the prostate cancer stem/progenitor cell population 
is enriched in Nanog (54). In bladder cancer higher Oct3/4 expression correlates with 
tumour progression and metastasis (20). Gidekel and colleagues showed that Oct3/4 
sets the oncogenic potential of germ-cell tumours and acted in a dose-dependent 
manner (39). It is notable to point out the reduction in the expression of pluripotency 
markers Oct3/4, Nanog and Sox2 observed in mammospheres of MDA-MB-231 after c-
Src suppression; indicating that c-Src is involved in the self-renewal ability of breast 
cancer stem cells in vitro by regulating the pluripotency-associated transcription factors 
Oct3/4, Nanog and Sox2. 
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1- The use of Dasatinib and PP2 revealed that SFKs catalytic activity is essential for 
MDA-MB-231 proliferation, since controls G1-S transition by regulating p27Kip1 and 
c-Myc expressions. However, SU6656 provoked multinucleated polyploid cells 
affecting Aurora B kinase activity, which regulates cytokinesis. This effect is 
independent of Src family kinase activity and is common to several breast cancer 
cell lines.  
 
2- Migration and invasion of MDA-MB-231 cells requires the kinase activity of SFKs, 
where c-Src plays an important role. These effects are mediated by 
phosphorylation of Y925-Fak, p130CAS, Y118-paxillin and Y14-caveolin 1, required 
for focal adhesion turnover, and cell motility. Furthermore, c-Src also controls 
secretion of matrix metralloproteases, MMP-2, MMP-7 and MMP-9 that degrade the 
components of extracellular matrix and therefore are important for cell invasive 
capacity. 
 
3- c-Src also modulates the secretion of proteins involved in breast cancer 
progression or metastasis, including Cyr61, IGFBP4 and CTGF. Furthermore, we 
found a new exosomal protein, Cyr61, involved in invasion and transedothelial 
migration processes of MDA-MB-231 cells. 
 
4- c-Src plays a key role in the anchorage-independent growth of MDA-MB-231 cells, 
which determines their ability to survive in absence of substrate, a fundamental 
step for the metastatic cascade.  
 
5- c-Src is required to maintain the breast cancer stem/progenitor cell subpopulation 
by regulating the expression of pluripotency-associated transcription factors Oct3/4, 
Nanog and Sox2. 
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1- El uso de Dasatinib y PP2 reveló que la actividad de las SFKs es esencial para la 
proliferación celular, ya que controla la transición G1-S, regulando la expresión de 
p27Kip1 y c-Myc. Sin embargo, SU6656 dio lugar a células poliploides 
multinucleadas al afectar a la actividad de Aurora B quinasa, que regula la 
citocinesis. Este efecto es independiente de la actividad quinasa de la familia Src y 
es común a varias líneas celulares de cáncer de mama. 
 
2- La migración e invasividad de las células MDA-MB-231, necesita la actividad 
quinasa de las SFKs, donde c-Src juega un papel importante. Estos efectos están 
mediados por la fosforilación de Y925-Fak, p130CAS, Y118-paxilina y Y14-
caveolina 1, las cuales son necesarias para el recambio de las adhesiones focales, 
y la motilidad celular. Además, c-Src también controla la secreción de las 
metaloproteasas de matriz, MMP-2, MMP-7 y MMP-9 que degradan componentes 
de la matriz extracelular y por tanto, son importantes para la capacidad celular 
invasiva. 
 
3- c-Src también modula la secreción de proteínas implicadas en la progresión o la 
metástasis del cáncer de mama, incluyendo, Cyr61, IGFBP4 y CTGF. Además, 
encontramos una nueva proteína exosomal, Cyr61, implicada en los procesos de 
invasividad y migración transendotelial de las células MDA-MB-231. 
 
4- c-Src tiene un papel importante en el crecimiento independiente de anclaje de las 
células MDA-MB-231, lo que determina su habilidad para sobrevivir en ausencia de 
sustrato, un paso fundamental para la cascada metastásica. 
 
5- c-Src es necesario para mantener la subpoblación de células 
troncales/progenitoras de cáncer de mama mediante la regulación de la expresión 
de los factores de transcripción asociados a pluripotencia, Oct3/4, Nanog y Sox2. 
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Appendix 
1.1. Supplementary information 
 
Supplementary Video S1. Normal mitosis in control MDA-MB-231 cells. The video shows 
an example of cells (arrows) that undergo normal mitosis, followed by complete cell division. 
(Video available in the attached CD). 
 
Supplementary Video S2. Blocked cell division in SU6656-treated MDA-MB-231 cells. The 
video shows aborted cell divisions (arrows) leading to the formation of cells displaying higher 
dimensions than no-dividing cells. (Video available in the attached CD). 
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Common pathways for Dasatinib, PP2 and SU6656 
Pathway name Source of annotation 
Gene 
set size 
DNA_REPLICATION KEGG 34 
CELL CYCLE, MITOTIC REACTOME 288 
G1/S TRANSITION REACTOME 96 
DNA REPAIR REACTOME 95 
G2/M CHECKPOINTS REACTOME 42 
ACTIVATION OF THE PRE-REPLICATIVE COMPLEX REACTOME 29 
EXTENSION OF TELOMERES REACTOME 23 
LAGGING STRAND SYNTHESIS REACTOME 19 
NUCLEOTIDE EXCISION REPAIR REACTOME 48 
PURINE_METABOLISM KEGG 146 
METABOLISM OF LIPIDS AND LIPOPROTEINS REACTOME 143 
DNA REPLICATION REACTOME 92 
E2F MEDIATED REGULATION OF DNA REPLICATION REACTOME 28 
CELL_CYCLE KEGG 112 
 
 
 
 
 
 
 
 
 
 
 
 
Pathway name Source of annotation Gene set size NES FDR q-val Sense 
SRC_GENES Custom 42 -1,19 0,19 DOWN in DAS 
SRC_GENES Custom 42 -1,35 0,083 DOWN in PP2 
SRC_GENES Custom 42 -1,51 0,024 DOWN in SU 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2. Gene set enrichment analysis was applied for each cell treatment 
using annotations from Biocarta, KEGG and Reactome pathway databases. Common 
pathways for each treatment with FDR ≤0.05 are shown. NES=Normalized Enrichment Score, 
FDR= False Discovery Rate. 
 (*Complete list of specific pathways for each treatment and the list of common pathways for two 
of the three inhibitors are available only in the electronic form in the attached CD). 
 
 
 
 
Supplementary Table 3. Ranked list of Src genes set for Dasatinib, PP2 and SU6656 
treated cells determined by GSEA. SU6656 treatment caused a significant down-regulation of 
Src pathway (FDR=0.024), while PP2 and DAS showed this trend but do not pass the 
significance threshold (FDR<0.05). NES=Normalized Enrichment Score, FDR= False Discovery 
Rate, Src gene set size = 42. 
 (*Complete ranked list of genes from Src pathway for each treatment is available only in the 
electronic form in the attached CD). 
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MDA-MB-231SFKs are frequently deregulated in cancer where they control cellular proliferation, migration, survival and
metastasis. Here we study the role of SFKs catalytic activity in triple-negative/basal-like and metastatic
human breast cancer MDA-MB-231 cells employing three well-established inhibitors: Dasatinib, PP2 and
SU6656. These compounds inhibited migration and invasion. Concomitantly, they reduced Fak, paxillin,
p130CAS, caveolin-1 phosphorylation and altered cytoskeletal structures. They also inhibited cell prolifera-
tion, but in different manners. Dasatinib and PP2 increased p27Kip1 expression and reduced c-Myc levels,
restraining G1–S transition. In contrast, SU6656 did not modify p27Kip1 expression, slightly altered c-Myc
levels and generated polyploid multinucleated cells, indicating inhibition of cytokinesis. These later effects
were also observed in SYF ﬁbroblasts, suggesting a SFKs-independent action. ZM447439, an Aurora B kinase
inhibitor, produced similar cell cycle and morphological alterations in MDA-MB-231 cells, indicating that
SU6656 blocked Aurora B kinase. This was conﬁrmed by inhibition of histone H3 phosphorylation, the canon-
ical Aurora B kinase substrate. Furthermore, hierarchical clustering analysis of gene expression proﬁles
showed that SU6656 deﬁned a set of genes that differed from Dasatinib and PP2. Additionally, Gene Set En-
richment Analyses revealed that SU6656 signiﬁcantly reduces the Src pathway. Together, these results show
the importance of SFKs catalytic activity for MDA-MB-231 proliferation, migration and invasiveness. They
also illustrate that SU6656 acts as dual SFKs and Aurora B kinase inhibitor, suggesting its possible use as a
therapeutic agent in breast cancer.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
SFKs regulate intracellular signaling pathways originated by acti-
vated transmembrane growth factors and cytokines receptors, includ-
ing EGF-R, PDGF-R, IGF-1R, VEGF-R, FGF-R, HER2, PRL-R, and E-R
[1–3]. Consequently, SFKs modulate signaling cascades leading to-R, epidermal growth factor re-
r; IGF-1R, insulin-like growth
factor receptor; FGF-R, ﬁbro-
RL-R, prolactin receptor; DAPI,
iazol-2-yl)-2,5-diphenyltetra-
um iodide; PARP, poly-ADP ri-
e Set Enrichment Analysis.
+34 91 585 4401.
).
rights reserved.cell proliferation, survival, differentiation, adhesion, migration, inva-
sion, etc., in several biological models [1,4].
Functional deregulation or altered expression of SFKs is associated
with human cancers [3,4]. Studies in human samples and animal
models support the role of SFKs catalytic activity in tumorigenesis
of breast, colorectal, pancreatic, prostatic, melanoma, gastric and
ovarian cancers [5]. In breast cancer, increased tyrosine kinase activ-
ity of c-Src is associated with induction, progression and metastasis
[3,6].
SFKs include nine members (c-Src, Blk, Fyn, Fgr, Hck, Lck, Lyn, Yes
and Yrk). They have a modular structure with a membrane-targeting
signal, Src homology domains SH2 and SH3 involved in protein–pro-
tein interactions. The kinase domain contains the ATP binding site
K298 and the autophosphorylation Y418 residue. Phosphorylation of
Y530 at carboxyl tail by CSK regulates kinase activity, as it favors in-
tramolecular interactions, which unable SH2, SH3 and catalytic do-
mains functionality [1,4].
1277M.P. Sánchez-Bailón et al. / Cellular Signalling 24 (2012) 1276–1286SFKs phosphorylate proteins involved in focal adhesion complexes
[1,4]. Upon interaction of Src-SH2 domain with auto-phosphorylated
Y397-Fak, Src becomes activated and phosphorylates Fak at multiple
sites including Y925 [7]. Src-Fak complex controls pathways leading
to proliferation, survival, focal adhesion and cytoskeleton remodeling
that have also implications in migration and invasiveness [4]. Like-
wise, Src-Fak complex phosphorylates proteins implicated in focal
adhesion, such as paxillin and p130CAS [1,4]. Src also phosphorylates
Y14-caveolin-1, which in turns acts as an effector of Rho/ROCK signal-
ing involved in migration and invasion of tumor cells by modulating
focal adhesion turnover [8,9]. Furthermore, SFKs catalytic activity is
also involved in cell cycle progression. Phosphorylated Y925-Fak by
Src serves as docking site for binding of P85-PI3K SH2 domain, lead-
ing to stimulation of PI3K/Akt pathway. Also, Src-Fak complex modu-
lates Mek1-2/Erk1-2 pathway [1,2,4].
We previously observed that SFKs catalytic activity regulates the
G1–S transition by controlling expression of c-Myc and p27Kip1 in
MCF7 and T47D non-metastatic human breast cancer cells [2,10]
and in lymphoid cells [11,12]. Src phosphorylates p27Kip1 on Y74/
Y88 facilitating its degradation and, as a result, facilitates G1–S transi-
tion [13]. In addition, Src promotes proliferation and survival by acti-
vating PI3K/Akt-dependent pathways [12,14].
Together, these data suggest that the SFKs catalytic activity is a
potential therapeutic target in several cancers. Thus, targeting the
catalytic domain has developed numerous kinase inhibitors, as ATP-
competitors. Because structural similarities of ATP pocket among ki-
nases, these compounds are not fully speciﬁc for SFKs, instead they
are considered as selective inhibitors [15]; such is the case of Dasati-
nib, PP2 and SU6656. Dasatinib is BCR/Abl and SFKs inhibitor that has
additional targets such as c-Kit, Eph kinases [16,17]; it is used in
chronic myelogenous leukemia (CML) and is under evaluation for
solid tumors including advanced prostate and breast cancer. PP2
shows also weak inhibition to other kinases including EGFR, CK1δ
and CSK [18]. SU6656 has some other targets identiﬁed in vitro:
PDGFR, BRSK2, AMPK, Aurora B kinase, and CaMKKβ [18]. The lack
of speciﬁcity of these inhibitors can be responsible for site-target ef-
fects when a single compound is used. To minimize this possible mis-
understanding, we carried out studies on the role of SFKs catalytic
activity in human triple-negative/basal like MDA-MB-231 breast can-
cer cells by employing Dasatinib, PP2 and SU6656.
We show that these three selective inhibitors of SFKs signiﬁcantly
reduced proliferation, migration and invasiveness. Particularly,
SU6656 blocked Aurora B kinase and induced polyploidy multinu-
cleated cells blocking cytokinesis. Hierarchical clustering analyses of
gene expression proﬁles show that SU6656 deﬁned an individual set
of genes that differed from Dasatinib and PP2. In contrast to them,
Gene Set Enrichment Analyses (GSEA) showed that SU6656 signiﬁ-
cantly reduced Src pathway.
2. Materials and methods
2.1. Reagents
Anti-c-Src 327 was from Calbiochem (Merck4Biosciences, Germa-
ny). Anti-Fak (A17), anti-p120-catenin (S-19) and anti-c-Myc
(N2E6.2) were from Santa Cruz Biotechnology (Santa Cruz, USA).
Anti-pY418-Src, secondary horseradish peroxidase-conjugated anti-
bodies, goat-anti-mouse IgG Alexa-Fluor 488, goat-anti-rabbit IgG
Alexa-Fluor 488 or 546 and ProLong antifade-reagent were from Invi-
trogen (Camarillo, USA). Anti-pY925-Fak, and anti-pY118-paxillin
were from Cell Signaling Technologies (Danvers, USA). Anti-paxillin,
anti-p130CAS, anti-caveolin, anti-pY14-caveolin, anti-β-catenin,
anti-p27Kip1, anti-BrdU FITC-conjugated and Matrigel™ were from
BD-Biosciences (Bedford, USA). Anti-pS10-histone H3 and anti-
phosphotyrosine 4G10 were from Millipore (Billerica, USA). Anti-
Aurora B and anti-histone H3 were from ABCAM (Cambridge, UK).Anti-α-tubulin, anti-β-actin, TRITC-labeled phalloidin, DAPI, MTT,
BrdU, trypan blue, propidium iodide (PI) and SU6656 were from
Sigma-Aldrich (St. Louis, USA). Puriﬁed histone H3 was from Roche
Applied Science (Indianapolis, USA). Acrylamide/Bis-acrylamide
(29:1), SDS and ammonium persulfate were from Bio-Rad Laborato-
ries (Hercules, USA). ECL was from GE Healthcare Biosciences (Pitts-
burgh, USA). BCA protein assay was from Thermo Scientiﬁc
(Rockford, USA). PP2 was from Tocris (Ellisville, USA), and Dasatinib
was from LC-Laboratories (Woburn, USA).
2.2. Cell cultures
MDA-MB-231 cells from ATCC were propagated in DMEM supple-
mented with 5% FCS, 2 mM glutamine, 100 IU/ml penicillin and
100 μg/ml streptomycin.
2.3. Metabolic activity and cell viability studies
For MTT assay, cells were 72 h-treated with DMSO (1:1000, Con-
trol), Dasatinib (10, 100, 500, 1000 nM), PP2 or SU6656 (1, 5, 25,
50 μM). Then, 10 μl of MTT reagent was added to each well (ﬁnal con-
centration 0.5 mg/ml) and plates were incubated at 37 °C for 4 h.
After solubilization of formazan crystals (2–3 h at 37 °C with 10%
SDS/10 mMHCl), absorbance was measured at 570 nm in a VersaMax
Elisa Microplate Reader (Molecular Devices, USA). Cell viability was
determined by counting cells with trypan blue. Cells were 72 h-trea-
ted with DMSO (Control), Dasatinib (100 nM), PP2 (5 μM) or SU6656
(5 μM), then detached, mixed with a 0.4% trypan blue/PBS solution
(1:1), loaded on a hemocytometer and counted.
2.4. Cell cycle analysis
Cell cycle studies were performed by double labeling with BrdU
and PI. Cells were pretreated with inhibitors (at concentrations de-
scribed above) for 2 h and pulsed for 30 min with BrdU (30 μM). Cul-
tures were washed with fresh medium and incubated in the presence
or absence of inhibitors for 3, 9, 24 and 36 h. Samples were prepared
as previously described [10].
For cell cycle studies with PI of 24 h- and 72 h-treated cells
(DMSO, 100 nM Dasatinib, 5 μM PP2, 5 μM SU6656 or 5 μM
ZM447439), samples were prepared as previously described [10].
Cell acquisition was performed with a FACScan ﬂow cytometer
(BD). At least 10,000 events/sample were acquired in linear (for PI)
and log (for FITC) mode. The proportion of cells in subG1, G1, S, G2/
M, and >4N phases was calculated with CellQuest software (BD).
2.5. Cell migration (wound healing assay)
Cells were seeded in complete medium (8×105 cells/60 mm
plate) and grown to conﬂuence. The monolayer was scratched with
a 200 μl micropipette tip and washed with fresh medium to remove
ﬂoating cells. Complete medium containing DMSO or inhibitors (con-
centrations as above) was added to cultures. Photomicrographs were
taken at 0 h and 20 h with a Nikon Eclipse TS100 inverted microscope
(Nikon, England), equipped with Olympus DP20 digital camera
(Olympus, Germany). Representative ﬁelds were photographed. As-
says were repeated 3 times. Magniﬁcation, ×100.
2.6. Invasion assay
Invasiveness was determined using cell culture inserts for 24-well
plate (8 μm-pore PET membranes) (BD). Filters were coated with
100 μl of ice-cold Matrigel diluted in DMEM basal medium and incu-
bated overnight at 37 °C. Cells were seeded on the upper chamber
(5×104/well/200 μl) in serum-free medium containing DMSO or in-
hibitors (see migration assay). The lower chamber was ﬁlled with
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24 h later, cells on the top of the inserts were removed and those on
the lower surface ﬁxed in methanol, stained with 10 μg/ml DAPI/PBS
and mounted on slides with ProLong antifade-reagent. Filters were
observed with a Plan 20×/0.50 objective using an Axiophot ﬂuores-
cence microscope (Zeiss, Germany) equipped with an Olympus
DP70 digital camera. DAPI-stained nuclei were counted. Assays were
performed in triplicate and repeated 4 times.
2.7. Immunoﬂuorescence and confocal microscopy
Cells seeded on sterile coverslips were 24 h-treated with DMSO or
inhibitors (see above), ﬁxed with 3.7% paraformaldehyde/PBS
(10 min, room temperature), permeabilized with 0.1% Triton X-100/
PBS (5 min, room temperature) and blocked 30 min with 1% BSA/
PBS. Coverslips were incubated 1 h at 37 °C with 1:200 TRITC-
labeled phalloidin (1:200 in PBS-1% BSA) or with anti-α-tubulin
(1:50), anti-phospho-histone H3 (1:200), then with goat-anti-
mouse IgG Alexa-Fluor 488 or goat-anti-rabbit IgG Alexa-Fluor 546
(1:200) for 1 h at 37 °C. After washing with PBS, cells were counter-
stained with 10 μg/ml DAPI/PBS for 10 min at 37 °C and coverslips
were mounted on slides with ProLong reagent. Samples were ob-
served and photographed with a Plan Apochromat 60×/1.40 objec-
tive using a Nikon Eclipse 90i ﬂuorescence microscope equipped
with Digital Sight DS-Qi1 camera and Nis-Elements BR imaging soft-
ware (Nikon).
For confocal microscopy experiments, cells were ﬁxed and per-
meabilized as above, saturated with 5% goat serum/PBS, and washed
with PBS-1% BSA. Samples were incubated with anti-pY118-Paxillin
(1:50), anti-pY925-Fak (1:50), anti-β-catenin (1:100), anti-p120-
catenin (1:100) and with the secondary antibody for 1 h at 37 °C.
Confocal images were acquired using an inverted Zeiss LSM 710
laser-scanning microscope with a Plan Apochromat 60×/1.40 objec-
tive. Sequential scanning mode was used to avoid crosstalk between
channels. Z-optical stacks with 0.6 μm intervals through the cell Z-
axis were recorded. Images were processed with ZEN 2009 software
(Zeiss) and Adobe Photoshop CS.
2.8. Time-lapse video microscopy
Live cell imaging was performedwith Microscope Cell Observer Z1
system (Carl Zeiss MicroImaging GmbH, Jena, Germany) equipped
with a controlled environment chamber (37 °C constant temperature,
5% CO2 atmosphere) and Camera Cascade 1k. MDA-MB-231 cells
were seeded in complete medium in 35 mm μ-dishes for live cell im-
aging (105 cells/dish) (Ibidi GmbH, Martinsried, Germany). After
24 h, cells were treated with DMSO (control) or SU6656 (5 μM). Im-
ages were collected every 15 min with a 20× Plan Apochromat objec-
tive, starting 3 h after inhibitor addition until 20 h of treatment. Time-
lapse movies were formatted using imaging software AxioVision 4.8
(Zeiss) and exported in QuickTime (Apple).
2.9. 3D cell culture assay
Three-dimensional (3D) analysis of morphology was performed as
previously described (G.Y. Lee, P.A. Kenny, E.H. Lee, M.J. Bissell, Na-
ture Methods, # 4923). Cell culture dishes (24-well plates) were pre-
coated with 50 μl of undiluted Matrigel (10 mg/ml) and incubated for
30 min at 37 °C to allow Matrigel to gel. Cells were prepared by tryp-
sinization from tissue culture plastic and resuspension in complete
medium (see “Cell cultures” section) for counting. To analyze the ef-
fects of SFK selective inhibitors on 3D cell growth, 104 cells (per
well of a 24-well plate) were resuspended in 300 μl of a mixture of
complete medium/Matrigel (1:3) containing DMSO (control), Dasati-
nib (100 nM), PP2 (5 μM) or SU6656 (5 μM). Then, they were seeded
over the geliﬁed coat Matrigel and incubated for at least 30 min at37 °C. 500 μl of complete medium containing DMSO or SFK selective
inhibitors was added to the cultures and changed every 2–3 days
until 21 days. To assess the effects of the inhibitors on MDA-MB-231
spheres already formed, drugs were added after a 21-day period of
growth and maintained for additional 7 days. Treatments were per-
formed in triplicate and assays were repeated 2 times. Cultures
were observed at 10× magniﬁcation under a Nikon Eclipse TS100
inverted microscope (Nikon Instruments Europe B.V., Kingston, Sur-
rey, England), equipped with Olympus DP20 digital camera (Olympus
Europe GmbH, Hamburg, Germany), and representative ﬁelds were
photographed.2.10. Western blotting
Cells were washed in ice-cold PBS and lysed, and Western blot
(WB) analyses of phospho-proteins/proteins were carried out as pre-
viously described [10].2.11. Aurora B kinase activity assay
Exponentially growing cultures were lysed at 4 °C in lysis buffer
(50 mM Hepes, pH 8, 600 mM KCl, 0.5% Nonidet P40, 1 mM Na3VO4,
1 mM DTT, 0.1 mM protease inhibitors). Aurora B kinase was immu-
noprecipitated from total cell extracts [19]. Immune-complexes
were incubated with histone H3 (1 μg) for 30 min at 37 °C in kinase
assay buffer (20 mM Hepes, pH 7.4, 150 mM KCl, 5 mM MnCl2,
5 mM NaF, 1 mM DTT, 30 μM cold ATP) in the presence or absence
of 1 μM SU6656. pS10-H3, H3 and Aurora B kinase expression were
determined by WB.2.12. Gene expression analyses
Cell cultures (70% conﬂuent) were treated with 100 nM Dasatinib,
5 μM PP2 or SU6656 for 72 h. RNA was isolated using RNeasy kit from
Qiagen (Valencia, USA) from three independent experiments carried
out in triplicate. After testing for RNA integrity, triplicate RNAs from
each treatment/experiment were pooled. Total RNA (10 μg) was
used to prepare probes, and then targets were hybridized to “Agilent
SurePrint G3 Human GE 8x60k Microarray” (Santa Clara, USA) follow-
ing manufacture instructions.
Analysis for differential expression was performed using the
Rplatform for statistical analysis (R Foundation for Statistical Com-
puting, Vienna) and several packages from the Bioconductor project
(http://www.bioconductor.org/). The raw data were imported into R
and preprocessed using the half method for background correction
and the quantile method for normalization. Probes with expression
level below the detection control probe in all samples were removed.
To identify differentially expressed genes, we used the limma pack-
age. Correction for multiple testing was accomplished by controlling
the false discovery rate using the method from Benjamini and Hoch-
berg [20]. Genes were selected as differentially expressed with Pad-
just ≤0.05. Hierarchical clustering analysis of gene expression
proﬁles was carried out using the complete linkage method.2.13. Gene Set Enrichment Analysis (GSEA)
Gene Set Enrichment Analysis [21] was applied using annotations
from BioCarta, KEGG and Reactome pathway databases together with
Src gene set previously reported [22]. Genes were ranked based on
limma moderated t statistic. After Kolmogorov–Smirnov testing,
those gene sets showing FDR ≤0.05, were considered signiﬁcantly
enriched among compared treatments.
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3.1. Effect of Dasatinib, PP2 and SU6656 on cell viability, SFKs kinase ac-
tivity, migration and invasiveness of MDA-MB-231 cells
To determine the concentrations of inhibitors to be used in our
study, we tested the effects of 72 h-treatment with different concen-
trations by MTT assay. As observed in Fig. 1A, at 100 nM Dasatinib
(Das) and at 5 μM PP2 and SU6656 (SU) the mitochondrial metabolicA
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Fig. 1. Effect of Dasatinib, PP2 and SU6656 on MDA-MB-231 viability, SFKs catalytic activit
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l in serum-free media containing DMSO (C), Das, PP2 or SU (as above). After 24 h, cells
s). Four independent experiments were made in triplicate. *Pb0.05, **Pb0.01 (Student
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231. When cultures were treated from the beginning, SU6656 inhib-
ited sphere formation (cells were not able to divide and showed en-
larged size), while Dasatinib and PP2 reduced sphere size. If
inhibitors were added after sphere formation (21 days), control sam-
ples showed continuously growing spheres (21+7 days-DMSO),
while in the presence of the inhibitors sphere size remained unal-
tered (21+7 days-PP2 or SU6656) or it clearly appeared reduced
(21+7 days-Dasatinib) (Suppl. Fig. 1). DAPI stain of ﬁxed spheres
seemed to exclude necrotic/apoptotic cells in treated 3D cultures
(data not shown).
Next, we veriﬁed if inhibitor concentrations that reduced cell via-
bility and proliferation were able to efﬁciently inhibit SFKs catalytic
activity. To this aim, exponentially growing cultures were treated
for 16 h with DMSO (vehicle), PP2, SU6656 or Dasatinib. Western
blot analyses of lysed cell with anti-phospho-Y418-Src showed that
all three compounds clearly reduced phosphorylation of Y418-Src
(Fig. 1B).
The oncogenic potential of increased SFKs catalytic activity in
tumor cells is pleiotropic and controls cytoskeletal-linked events,
such as extracellular matrix-adhesion, migration, and invasion,
which are associated to SFKs substrates including Fak, p130CAS
and paxillin involved in integrin signaling and in adhesion dynam-
ics [1,4]. We have then analyzed whether SFKs inhibitors affected
the phosphorylation of these proteins. Phosphorylation of Y925-
Fak by Src observed in DMSO-treated cells was inhibited upon
24 h treatment with Dasatinib, PP2 or SU6656 (Fig. 1C).
Activated Src-Fak complex engages and phosphorylates other pro-
teins of focal adhesion complex, including paxillin and p130CAS [10].
Dasatinib, PP2 or SU6656, employed as above, strongly reduced Y118-
paxillin phosphorylation as compared to DMSO-treated cells. Like-
wise, the amount of tyrosine-phosphorylated p130CAS was also di-
minished (Fig. 1C, IP p130CAS/WB pY).
Caveolin-1, a multifunctional membrane protein responsible for
caveolae formation, is phosphorylated by SFKs at Y14 and mediates
tumor migration and invasion through Rho/ROCK [9]. As observed
here, these inhibitors clearly reduced pY14-caveolin as compared to
control cells (Fig. 1C). Furthermore, we tested by confocal microscopy
the expression and distribution of pY118-paxillin and pY925-Fak and
their relationship with actin cytoskeleton (phalloidin-TRITC labeling).
In control cells pY118-paxillin and pY925-Fak accumulated in focal
adhesion area; after inhibitor treatments a consistent reduction of
pY118-paxillin and pY925-Fak was observed (Suppl. Figs. 2 and 3).
Actin cytoskeleton, characterized by stress ﬁbers in untreated sam-
ples, showed a thickness of these structures at the cell edge after
PP2 treatment. Dasatinib caused alterations of cytoskeleton structure
with collapse of actin microﬁlaments. SU6656-treated cells main-
tained actin stress ﬁbers, although in some cells, a thickening of
these ﬁlaments was observed at the edges (Suppl. Figs. 2 and 3).
Since these inhibitors altered focal adhesion molecules and actin
structures, we analyzed subcellular localization of β-catenin and
p120 catenin. Treatments increased membrane-localized β-catenin
and p120 catenin (Suppl. Figs. 4 and 5), while the total levels of
both proteins remained unchanged, as observed by Western blot
(data not shown).
Inhibition of focal adhesion protein phosphorylation and altered
cellular distribution of catenins should lead to a reduction in adhesion
dynamics and to inhibition of migration and invasion. To test this hy-
pothesis, we determined the migration and invasion capability of
MDA-MB-231 cells upon treatment with SFKs inhibitors. Migration
assayed by wound healing repair showed that control cells migrated
to heal the wound. Treatments with Dasatinib, PP2 and SU6656 clear-
ly reduced cell migration (Fig. 1D). For invasion assay, cells treated
with DMSO, Dasatinib, PP2 or SU6656 were loaded on the top of
Matrigel in a Boyden chamber; those able to move throughout this
extracellular matrix were then counted as a measurement of invasion(see Materials and methods). All three inhibitors signiﬁcantly re-
duced cell invasion (Fig. 1E), suggesting that SFKs catalytic activity
is involved in MDA-MB-231 cell migration and invasion processes.
3.2. Effects of SFKs inhibitors on cell cycle progression and morphology of
MDA-MB-231 cells and SYF ﬁbroblasts
Inhibition of cell proliferation induced by SFKs inhibitors could be
ascribed to alteration of cell cycle progression. Studies performed by
double labeling with BrdU and PI showed that treatment with Dasati-
nib or with PP2 induced G1 accumulation and reduced the number of
cells in S or G2/M compartments as compared to control cells
(Fig. 2A). Surprisingly, SU6656 caused an aberrant cell cycle; G1 and
S phases decreased with time, and the G2/M started to decline after
24 h. A new set of cells that accumulated DNA (>4N) increased con-
stantly (Fig. 2A). Thus, Dasatinib and PP2 appeared to affect G1–S
transition, while SU6656 generated polyploidy.
To conﬁrm these results, cell cycle was analyzed at longer time
(72 h) by PI labeling. Dasatinib and PP2 caused accumulation of
cells in G1 and reduced the number of cells in S and G2/M phases.
The >4N compartment was minimal as in control cells (Fig. 2B).
SU6656 reduced cells in G1 and S compartments, increased cells
in G2/M and provoked a 60% increase of polyploid cells (Fig. 2B).
Consistently, this compound did not inhibit DNA duplication, but
it probably blocked completion of cell cycle, which is reliable with
the strong reduction of cell number determined by trypan blue
(Fig. 1A). It should be noticed that, besides the absence of cells in
Sub-G1, no PARP degradation was detected (data not shown), sug-
gesting that these compounds, under these experimental condi-
tions, did not induce apoptosis.
In agreement with accumulation of cells in G1 upon treatment
with Dasatinib and PP2, p27Kip1 expression increased and c-Myc
levels decreased as compared to control growing cells (Fig. 2C).
Since SU6656 did not alter G1–S transition, expression of p27Kip1
and c-Myc were similar to control cultures (Fig. 2C).
The differential effects induced by SU6656 as compared to Dasati-
nib and PP2 on viability, proliferation and cell cycle progression may
be reﬂected on cell morphology. Then, we carried out double immu-
noﬂuorescence labeling of nuclei and microtubules (see Materials
and methods). Dasatinib-treated cells showed partially collapsed mi-
crotubule structure deﬁning a pseudo-spherical shape (Fig. 2D). Tu-
bulin staining pattern induced by PP2 was relatively similar to
control cells, although cells adopted an elongated morphology
(Fig. 2D). In SU6656-treated cells, microtubule cytoskeleton was
also maintained. However, cell size clearly increased and multinu-
cleation was induced (arrows indicated an example of several nuclei
within a cell) (Fig. 2D), supporting the hypothesis that SU6656
blocked cell division.
To conﬁrm this blockage, we carried out a 24 h video-
microscopy of cells treated with DMSO or with SU6656. While con-
trol cells divided along the time course of the experiment, SU6656-
treated cells detached from the culture plate and before completing
cell division re-attached giving rise to bigger multinucleated cells
(Suppl. Videos 1 and 2).
These ﬁndings suggest that SU6656, in addition to inhibit SFKs,
was affecting other targets that, in turn, could account for this unusu-
al response as compared to Dasatinib and PP2. To support this hy-
pothesis, we investigated whether SU6656 provoked similar cell
cycle and morphological alterations in cells that do not express
SFKs, such as mouse SYF ﬁbroblast derived from triple deletion of c-
src, yes and fyn [23]. Cell cycle analyses after PI labeling showed that
24 h treatment with Dasatinib or PP2 had no effects as compared
with DMSO-treated cells (Fig. 3A), which is consistent with the fact
that SYF ﬁbroblasts do not express SFKs. SU6656 strongly reduced
cells in G1 and S phases and increased the number of cells in G2/M
and >4N compartments (Fig. 3A). Consistently, Dasatinib or PP2 did
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Fig. 2. Effects of Dasatinib, PP2 and SU6656 onMDA-MB-231 cell cycle progression, p27Kip1 and c-Myc expression, morphological features. A) Cell cycle analysis by pulse/chase BrdU
and PI labeling of cells treated with DMSO (Control), Dasatinib (100 nM), PP2 (5 μM) or SU6656 (5 μM). Cells were collected at indicated times and analyzed by ﬂow cytometry.
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cence of cultures treated with DMSO (Control), Dasatinib, PP2 and SU6656 (as above) for 24 h. Cells were labeled for DNA (DAPI, blue) and for microtubules (anti-α-tubulin, green).
Representative images captured with a Nikon Eclipse 90i ﬂuorescence microscope. Bar=10 μm. Arrows show a multinucleated cell.
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tures (Fig. 3B). In contrast, SU6656 produced enlargedmultinucleated
cells (arrows indicated several nuclei within a cell) (Fig. 3B). Togeth-
er, these results resemble those induced by SU6656 in MDA-MB-231
cells (Fig. 2B and D). It should be noted that SU6656 caused similar al-
terations in MCF7 and SUM159 human breast cancer cell lines (data
not shown), suggesting that SU6656-mediated cell cycle alteration
is a common effect in breast cancer cells.
3.3. Differential effects of SU6656 versus Dasatinib and PP2: inhibition of
Aurora B kinase
Blockage of cell division by SU6656 suggests that a kinase in-
volved in regulation of mitosis and cell division could also be affect-
ed. Among these enzymes, Aurora B kinase, which inhibition causes
polyploidy in a variety of human tumor cell lines [24], is inhibitedin vitro by SU6656 [18,25]. Therefore, we compared the effects of
SU6656 (5 μM) and ZM447439 (5 μM), a selective inhibitor of Auro-
ra B kinase [19,26], on cell cycle progression and morphology of
MDA-MB-231 cells. After 24 h treatment, cell cycle analyses by PI
labeling showed that both inhibitors reduced cells in G1 and S
phases and robustly increased cells in G2/M and >4N compart-
ments (Fig. 4A). Immunoﬂuorescence analyses showed that both
SU6656 and ZM447439 induced multinucleated cells (arrows indi-
cated several nuclei within a cell) (Fig. 4B). Since serine-10 of his-
tone H3 is a canonical substrate for Aurora B kinase [19,24,26,27],
we investigated whether SU6656 blocked this phosphorylation,
using ZM443979-treated cells as a positive control. Exponentially
growing cultures treated 24 h with SU6656 or with ZM443979
showed strong reduction of pS10-H3 as compared to control cul-
tures (Fig. 4C). We then immunoprecipitated Aurora B kinase
from cultures treated for 24 h with DMSO or with SU6656 and
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Fig. 3. Effects of Dasatinib, PP2 and SU6656 in SYF ﬁbroblasts. A) Cell cycle analyses of SYF cells treated with DMSO (C), Das (100 nM), PP2 (5 μM) and SU (5 μM) for 24 h. PI labeling
was carried out as in Fig. 2B. B) Cultures treated as above were labeled with DAPI and with anti-α-tubulin and analyzed by immunoﬂuorescence as in Fig. 2D. Arrows indicate a
multinucleated cell. Bar=10 μm.
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strate (see Materials and methods). The level of pS10-H3 detected
in immuno-complexes from SU6656 treated cells was strongly di-
minished as compared to those from control cells (Fig. 4D). As the
amounts of H3 and Aurora B kinase in the immuno-complex reac-
tions were similar, it can be argued that SU6656 inhibited Aurora
B kinase activity in MDA-MB-231 cells. Fluorescence microscopy
of mitotic cells stained with DAPI, α-tubulin and pS10-H3 con-
ﬁrmed these results. As compared to control cells, 24 h treatment
with SU6656 or with ZM443979 induced the appearance of cells
with multiple spindle poles and drastic reduction of pS10-H3
staining (Fig. 4E), a characteristic phenotype of Aurora B kinase-
inhibited cells [28]. Together these data showed that SU6656
mimicked the effects of ZM443979 in cell cycle, morphology and
histone H3 phosphorylation and suggest that SU6656 inhibited
cell division of MDA-MB-231 cells by blocking the functionality
of Aurora B kinase.3.4. Differential gene expression induced by Dasatinib, PP2 and SU6656
In view of the differential responses of SU6656 versus Dasatinib
and PP2 for cell cycle regulation, we engaged analyses of gene expres-
sion proﬁles induced by these compounds. All studies were carried
out in triplicate and RNA was used to hybridize Agilent microarrays.
One of SU6656 triplicate was discarded because it did not pass quality
control standards. All treatments resulted in gene expression
changes. Using a statistical cut-off of Padjust ≤0.05, we obtained
1866 differentially expressed probes (1641 annotated sequences)
after Dasatinib treatment, 21 after SU6656 (15 annotated sequences)
and 16 probes after PP2 treatment. The complete list of genes is pro-
vided in Suppl. Table 1. The hierarchical clustering of all individual
data representing all selected differentially expressed sequences isshown in Fig. 5A. The columns contain data for individual samples,
which clustered in four groups as a function of treatment, and indicat-
ed that replicates were fairly homogeneous. The rows show relative
intensities of the probes and deﬁned twomain clusters of differential-
ly expressed genes, having higher or lower expression after treat-
ments. The results revealed that the effects of Dasatinib were
more pronounced than those of PP2, although in most cases
there was also an effect, but of lower intensity. This gene expres-
sion pattern did not correspond to that observed for SU6656 treat-
ment, which is more similar to DMSO-treated cells (Control). The
comparisons of each individual treatment versus control using
plot proﬁle representations are shown in Fig. 5B. These plots
show expression values along different samples for probes selected
as differentially expressed in the three treatment groups. The data
indicated again that Dasatinib produced large changes of gene ex-
pression that diverged to control and SU6656 samples and to
lower degree to PP2. Although only a reduced number of genes
passed the statistical analysis after PP2 treatment, the plots
showed that there was a great agreement between PP2 and Dasa-
tinib. The PP2 versus Control analysis showed two main clusters,
PP2-Dasatinib, and SU6656-Control. Instead, in the evaluation of
SU6656 versus Control, a set of genes deﬁned in an individual
group that differed from the rest of treatments. In addition, almost
all genes selected in PP2 and Dasatinib groups did not alter their
expression after SU6656 treatment.
Furthermore, to study pathways of gene expression related to
biological functions analyzed above upon different treatments,
GSEA [21] was applied using annotations from BioCarta, KEGG and
Reactome pathway databases together with Src gene set previously
reported [22]. The analyses (Suppl. Table 2) showed that most of
the pathways detected were down regulated in each treatment. Ex-
ceptionally, glycolysis was upregulated in Dasatinib-treated cells,
while asthma and autoimmune thyroid disease were increased in
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1283M.P. Sánchez-Bailón et al. / Cellular Signalling 24 (2012) 1276–1286PP2-treated cells. Some pathways were shared by Dasatinib, PP2
and SU6656, while others appears to be more speciﬁc. These path-
ways can be summarized in main categories. Common to all three
treatments are pathways involved in different processes of cell
cycle regulation, immune system and metabolism of lipids and lipo-
proteins. Dasatinib and PP2 shared pathways involved in signaling
by EGFR in cancer, by GPCR and by NGF. In addition of cell cycleregulation, metabolism of carbohydrates was common in PP2 and
SU6656, while pathways involved in renal cell carcinoma, pancreat-
ic, bladder and colorectal cancer and WNT signaling appeared to be
speciﬁc for SU6656. Interestingly, GSEA analyses of Src gene path-
way (Suppl. Table 3) showed a signiﬁcant reduction upon SU6656
treatment (FDR=0.024), while PP2 and Dasatinib treatments had
FDR >0.05 (0.083 and 0.193, respectively).
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B) Comparisons between effects of Dasatinib, PP2 and SU6656 treatments are shown in plot proﬁles. Signal intensities are normalized as in the heat map and expression values are
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SFKs regulate signaling pathways engaged in the control of many
cellular processes. As they are frequently deregulated in numerous
tumors including breast cancer [3–6], their catalytic activity has
been considered as a target for cancer therapy. Since there are not
fully speciﬁc inhibitors of SFKs, here, we studied the role of SFKs cat-
alytic activity in human triple-negative/basal-like MDA-MB-231
breast cancer cells employing Dasatinib, PP2 and SU6656 selective in-
hibitors. Interestingly, while these compounds inhibited pY418-Src,
GSEA analysis showed that Src gene set expression was signiﬁcantly
reduced by SU6656. All three compounds signiﬁcantly reduced cellu-
lar proliferation, migration and invasion.
SFKs, directly or through a complex with Fak, control pathways in-
volved in the dynamics of focal adhesions, which are engaged in the
regulation of cellular migration and invasiveness [1,4]. Thus, Src/Fak
phosphorylates proteins of the focal adhesion complex including pax-
illin, p130CAS, as well as caveolin-1. Consistent with inhibition of
SFKs catalytic activity by Dasatinib, PP2 and SU6656, tyrosine phos-
phorylation of paxillin, p130CAS and caveolin-1 was reduced, cyto-
skeleton architecture was altered and cellular migration and
invasiveness were also inhibited. In this context, we previously
showed that the functionality of SFKs was essential for cellular migra-
tion, spreading and adhesion of MCF7 cells [10]. Here, we observed
that migration of SYF ﬁbroblasts, which lack SFKs, was not altered
by Dasatinib, PP2 or SU6656 treatments (data not shown). Together,
these data suggest that reduction caused in MDA-MB-231 cells by
these compounds could be ascribed to inhibition of SFKs catalytic
activity.
Concomitantly, GSEA analysis of the gene expression patterns
showed that these inhibitors also down-regulated several pathways
associated with migration, cell motility and cytoskeleton reorganiza-
tion, which in turn could affect cell invasion.
Studies in different tumor cells support these results. Dasatinib
reduced migration and invasion in head and neck squamous cell
carcinoma, non-small cell lung cancer [29] and in breast cancer
cell lines [30,31]. Interestingly, basal-like/triple-negative breast
cancer cell lines with high levels of caveolin-1 expression, like
MDA-MB-231 cells, are characterized by sensitivity to Dasatinib,
while low expression of caveolin-1 correlates with resistance
[32]. In MDA-MB-231 and BT-549, inhibition of SFKs by SU6656
suppresses invadopodia formation while enhances tubulin-based
microtentacle, effects associated with reduced cellular invasion
[33]. PP2 also inhibits invasion in MDA-MB-231 [34] and ovarian
cancer cells [35].
Dasatinib, PP2 and SU6656 signiﬁcantly reduced cell proliferation
and speciﬁcally altered cellular morphology. Dasatinib generated
pseudo-spherical cells, PP2 caused elongated spindle morphology and
SU6656 produced ﬂattened enlarged cells, indicating that they
affected additional targets. SU6656 similarly altered morphology of
SYF ﬁbroblasts, while Dasatinib and PP2 did not. Therefore, the
changes induced by SU6656 in MDA-MB-231 seem to be indepen-
dent on SFKs catalytic activity. Our results concerning effects of
Dasatinib on cell proliferation are similar to those previously de-
scribed [30]. Others have reported that Dasatinib induces cell death
and apoptosis in tumor cell lines including MDA-MB-468 [36], head
and neck squamous cell carcinoma, non-small cell lung cancer cells
and in osteosarcoma and Ewing's subset of bone sarcomas [29,37].
In contrast, in our study Dasatinib, PP2 and SU6656 did not induce
cytotoxic effects.
Concomitant with inhibition of cell proliferation, Dasatinib and
PP2 reduced c-Myc expression and increased p27Kip1 levels, which
are consistent with a blockage of cell cycle progression in G1. Dasati-
nib and PP2 produced similar results in studies conducted in MDA-
MB-231, W53 lymphoid cells, MCF7 and in ovarian cancer cells
[2,11,30,35]. Also, interfering SFKs functionality by conditionalexpression of SrcDN in MCF7 cells causes accumulation in G1 and in-
creased p27Kip1 expression [10].
Interestingly, SU6656 neither blocked G1 to S transition, nor in-
duced p27Kip1 expression, causing only a small reduction of c-Myc
levels. Instead, SU6656 caused polyploidy. These ﬁndings could ex-
plain the quantitative differences observed between trypan blue
and MTT proliferation assays. In trypan blue assays, SU6656 in-
duced an inhibitory effect more evident (80%) than Dasatinib or
PP2 (25–35%), while in MTT assays the inhibition was quite similar
(approximately 45%). Analyzing cell cycle progression with BrdU/PI
labeling at 24 h or with PI at 72 h solved discrepancy between
these two methods. In both assays, Dasatinib and PP2 increased
cell number in G1, suggesting that they blocked G1–S transition.
Consistently, GSEA analysis showed that G1/S transition pathway
(Reactome) is down regulated in Dasatinib and PP2-treated cells
(FDR ≤1×10−6). In contrast, SU6656 caused accumulation of
large polyploid multinucleated cells, suggesting that it did not
block cell cycle at a particular phase. Instead, cells seemed to
enter and go out of mitosis but failed to divide. This implies that
cell continued to be metabolically active in order to synthesize all
components necessary for cycling, which explains higher values
obtained with MTT than with trypan blue assay. Indeed, time-
lapse video microscopy showed that SU6656 treated cells detached
from the substrate just before cell division but, in contrast to divid-
ing control cells, they re-attached and did not complete cytokinesis,
generating enlarged cells. SU6656 also induced polyploidia and
multinucleation of SUM159 and MCF7 human breast cancer cell
lines (data not shown). Since MCF7 has a functional p53, while
MDA-MB-231 and SUM159 have p53 mutated [38], these effects
appear to be p53 independent.
Polyploidy has been also observed in B-lymphocytes, non-
Hodgkin's lymphoma and megakaryocytic cells upon treatment with
SU6656 [25,39]. SU6656 caused similar effects in SYF, indicating
that SU6656 is targeting additional kinases involved in cell division.
Indeed, SU6656 inhibits Aurora B kinase in vitro [18]. It is well estab-
lished that Aurora B kinase, in addition to phosphorylate S10-H3, is a
spindle checkpoint kinase required for cytokinesis and its inhibition
eliminates mitotic checkpoint generating polyploid multinucleated
cells [24]. We found that ZM447439, a known inhibitor of Aurora B ki-
nase [19,26], produced similar effects as SU6656 in cell cycle progression,
morphological alterations and inhibition of S10-H3 phosphorylation in
MDA-MB-231 cells. Furthermore, SU6656 also inhibited Aurora B kinase
in these cells. Similar results were observed in megakaryocytic [25] and
MCF7 cells [27].
Since Aurora B kinase is required for completion of mitosis, chro-
mosome segregation and cytokinesis, and is up-regulated in a variety
of tumors, it is considered as relevant target in cancer therapy [40,41].
In this context, AZD1152, another Aurora B kinase inhibitor, blocks
proliferation in human breast cancer cell lines and reduces lung me-
tastasis of MDA-MB-231 in nude mouse [42].
In conclusion, our results in human metastatic breast cancer
cells indicate that SFKs catalytic activity is required for proliferation,
migration and invasiveness, through the regulation of molecular
pathways involved in these cellular processes. Of particular interest
is SU6656 that being a dual SFKs/Aurora B kinase inhibitor could
have a potential use as a therapeutic agent in metastatic breast
cancer.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.cellsig.2012.02.011.
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